

# Nrf2 deficiency aggravates PM<sub>2.5</sub>-induced cardiomyopathy by enhancing oxidative stress, fibrosis and inflammation via RIPK3-regulated mitochondrial disorder

Chenxu Ge<sup>1,2,3,\*</sup>, Linfeng Hu<sup>1,2,3,\*</sup>, Deshuai Lou<sup>1,3,\*</sup>, Qiang Li<sup>1,3</sup>, Jing Feng<sup>1,3</sup>, Yekuan Wu<sup>1,3</sup>, Jun Tan<sup>1,3</sup>, Minxuan Xu<sup>1,2,3</sup>

<sup>1</sup>Chongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing 400067, PR China

<sup>2</sup>Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, China

<sup>3</sup>Research Center of Brain Intellectual Promotion and Development for Children Aged 0-6 Years, Chongqing University of Education, Chongqing 400067, PR China

\*Equal contribution

**Correspondence to:** Jun Tan, Minxuan Xu; **email:** [tanjun@cque.edu.cn](mailto:tanjun@cque.edu.cn), [minxuanxu@foxmail.com](mailto:minxuanxu@foxmail.com)

**Keywords:** PM<sub>2.5</sub>, cardiomyopathy, Nrf2, RIPK3, mitochondrial dysfunction

**Received:** November 13, 2019

**Accepted:** February 5, 2020

**Published:** March 17, 2020

**Copyright:** Ge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

PM<sub>2.5</sub> is a well-known air pollutant threatening public health, and long-term exposure to PM<sub>2.5</sub> increases the risk of cardiovascular diseases. Nrf2 plays a pivotal role in the amelioration of PM<sub>2.5</sub>-induced lung injury. However, if Nrf2 is involved in PM<sub>2.5</sub>-induced heart injury, and the underlying molecular mechanisms have not been explored. In this study, wild type (Nrf2<sup>+/+</sup>) and Nrf2 knockout (Nrf2<sup>-/-</sup>) mice were exposed to PM<sub>2.5</sub> for 6 months. After PM<sub>2.5</sub> exposure, Nrf2<sup>-/-</sup> mice developed severe physiological changes, lung injury and cardiac dysfunction. In the PM<sub>2.5</sub>-exposed hearts, Nrf2 deficiency caused significant collagen accumulation through promoting the expression of fibrosis-associated signals. Additionally, Nrf2<sup>-/-</sup> mice exhibited greater oxidative stress in cardiac tissues after PM<sub>2.5</sub> exposure. Furthermore, PM<sub>2.5</sub>-induced inflammation in heart samples were accelerated in Nrf2<sup>-/-</sup> mice through promoting inhibitor of  $\alpha$ /nuclear factor  $\kappa$ B (I $\kappa$ B $\alpha$ /NF- $\kappa$ B) signaling pathways. We also found that Nrf2<sup>-/-</sup> aggravated autophagy initiation and glucose metabolism disorder in hearts of mice with PM<sub>2.5</sub> challenge. Cardiac receptor-interacting protein kinase 3 (RIPK3) expression triggered by PM<sub>2.5</sub> was further enhanced in mice with the loss of Nrf2. Collectively, these results suggested that strategies for enhancing Nrf2 could be used to treat PM<sub>2.5</sub>-induced cardiovascular diseases.

## INTRODUCTION

Fine particulate matter 2.5 (PM<sub>2.5</sub>) is a collective term referring to atmospheric fine particles, which is regarded as one of the most essential air pollutants in many cities of China [1, 2]. Epidemiological studies have reported that long term exposure to high concentrations of airborne fine PM<sub>2.5</sub> increases the risk of respiratory and cardiovascular diseases, and

animal experiments have showed that PM<sub>2.5</sub> could induce cardiovascular dysregulation [3–5]. Accumulating evidences demonstrate that the production of ROS, inflammatory responses, calcium homeostasis imbalance and fibrosis are involved in PM-associated cardiovascular disease [6–8]. Nevertheless, there has been only limited data on the detailed molecular mechanisms of PM<sub>2.5</sub>-induced cardiac injury.

Nuclear factor erythroid 2-related factor 2 (Nrf2), a redox-sensitive transcription factor, promotes a battery of antioxidant genes and cytoprotective enzymes that constitute the defense against oxidative stress [9]. Nrf2 activation could protect the heart against ischemia reperfusion injury and diabetic cardiomyopathy [10, 11]. Under normal conditions, Nrf2 is bound to Kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm. However, upon exposure to stressors or inducers, the release of Nrf2 from Keap1 translocates into the nuclear to promote the expression of multiple cytoprotective genes, such as HO1, NAD(P)H: quinone oxidoreductase 1 (NQO1) and glutamate-cysteine ligase modifier (GCLM) [12, 13]. In addition, Nrf2 could modulate the expression of numerous anti-inflammatory and pro-fibrotic genes by antioxidant response elements in their promoters to neutralize free radicals and enhance removal of environmental toxins [14]. Our previous studies indicated that PM<sub>2.5</sub>-induced hypothalamus inflammation and renal injury were associated with the deregulation of Nrf2 signaling, which subsequently influenced inflammatory response both *in vivo* and *in vitro* [15, 16]. In addition, prolonged PM<sub>2.5</sub> exposure elevates risk of oxidative stress-driven nonalcoholic fatty liver disease partly through the irregular modulation of Nrf2 [17]. Recently, therapeutic strategy to induce Nrf2 expression was effective for the prevention of PM<sub>2.5</sub>-induced lung injury [18]. Considering the critical role of Nrf2 in regulating cardiovascular disease and PM<sub>2.5</sub>-induced tissue injuries, we hypothesized that Nrf2 might also be involved in PM<sub>2.5</sub>-induced heart dysfunction and injury.

The mitochondrion is a sensitive target of both oxidative stress and environmental toxicants stimulus like PM<sub>2.5</sub> [19, 20]. The abnormal condition of mitochondrial fission and fusion may lead to the irregular alterations of mitochondrial structure and function, which could contribute to respiratory diseases [21]. PM<sub>2.5</sub> may result in mitochondrial injury in exposed individuals, which in turn at least partly modulates PM-induced cardiovascular injury [22]. The receptor-interacting protein kinase-3 (RIPK3) is a cardinal regulator of necroptosis, and has recently been involved in the pathogenesis of human disease [23, 24]. Recent studies have indicated the increased expression of RIPK3 in murine models of cardiac ischemia/reperfusion injury [25]. We also found that suppressing RIPK3 could alleviate high fat diet-induced hepatic injury partially through the regulation of Nrf2 signaling [26]. Recently, RIPK3 was reported to promote sepsis-triggered acute kidney injury by enhancing mitochondrial dysfunction [27]. Along with the well-documented role of RIPK3-

mediated mitophagy in tissue injury, we asked if RIPK3-regulated mitochondrial function could be regulated by Nrf2 in the setting of PM<sub>2.5</sub>-induced cardiomyopathy.

In this study, the wild type (Nrf2<sup>+/+</sup>) and Nrf2 knockout (Nrf2<sup>-/-</sup>) mice were exposed to either ambient PM<sub>2.5</sub> or filtered air (FA) for 6 months, and then the oxidative stress, fibrosis, inflammation, autophagy, glucose metabolism, RIPK3 expression and mitochondrial function in the hearts were investigated.

## RESULTS

### Effects of Nrf2 deficiency on physiological changes, lung and heart injuries in PM<sub>2.5</sub>-exposed mice


In order to investigate the effects of Nrf2 on PM<sub>2.5</sub>-induced cardiomyopathy, Nrf2<sup>+/+</sup> and Nrf2<sup>-/-</sup> mice were used in our present study. Nrf2 was hardly detected in heart and lung tissue samples of Nrf2<sup>-/-</sup> mice (Supplementary Figure 1A). As shown in Figure 1A, no significant difference was observed in the change of body weight between the Nrf2<sup>+/+</sup>/FA and Nrf2<sup>+/+</sup>/PM<sub>2.5</sub> groups, or the Nrf2<sup>+/+</sup>/PM<sub>2.5</sub> and Nrf2<sup>-/-</sup>/PM<sub>2.5</sub> groups. Significant enhancements of blood glucose were observed in Nrf2<sup>+/+</sup>/PM<sub>2.5</sub> mice compared to Nrf2<sup>+/+</sup>/FA group. Higher blood glucose levels were detected in Nrf2<sup>-/-</sup>/PM<sub>2.5</sub> group of mice than that in the Nrf2<sup>+/+</sup>/PM<sub>2.5</sub> group (Figure 1B). Long term exposure of PM<sub>2.5</sub> led to significant increases in the mean blood pressure (MBP) of Nrf2<sup>+/+</sup> mice compared with Nrf2<sup>+/+</sup>/FA mice, which was further accelerated in PM<sub>2.5</sub>-exposed mice with Nrf2<sup>-/-</sup> (Figure 1C). Subsequently, H&E staining revealed that Nrf2<sup>-/-</sup> lungs and hearts developed significantly more severe injury than Nrf2<sup>+/+</sup> lungs in response to PM<sub>2.5</sub> (Figure 1D). Moreover, PM<sub>2.5</sub> exposure led to markedly more levels of total cell and higher protein concentration in bronchoalveolar lavage fluid (BALF) from Nrf2<sup>-/-</sup> mice compared with that from Nrf2<sup>+/+</sup> mice (Figure 1E and 1F). PM<sub>2.5</sub>-exposure resulted in higher serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels; however, these increases were obviously stronger in serum of Nrf2<sup>-/-</sup> mice (Figure 1G and 1H). Together, Nrf2 deficiency accelerated PM<sub>2.5</sub>-induced physiological changes, pulmonary and cardiac injuries.

### Nrf2 deletion accelerates cardiac dysfunction and fibrosis in PM<sub>2.5</sub>-exposed mice

In this regard, the effects of Nrf2 deletion on PM<sub>2.5</sub>-induced cardiomyopathy were further investigated. As shown in Figure 2A and 2B, long term exposure of PM<sub>2.5</sub> led to significant increases in the heart weight and

the ratio of heart weight to body weight compared to FA mice from *Nrf2*<sup>+/+</sup> group. Though *Nrf2*<sup>-/-</sup> promoted these increases, no significant difference was detected after PM<sub>2.5</sub> stimulation in both genotypes (Figure 2A and 2B). The mRNA levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), as essential

markers for cardiac hypertrophy that indicates heart injury [28], were significantly up-regulated by PM<sub>2.5</sub> in *Nrf2*<sup>+/+</sup> mice, and these effects were further accelerated in *Nrf2*<sup>-/-</sup> mice after PM<sub>2.5</sub> exposure (Figure 2C). Furthermore, echocardiography analysis demonstrated that PM<sub>2.5</sub>-induced cardiac dysfunction was



**Figure 1. Effects of *Nrf2* deficiency on physiological changes, lung and heart injuries in PM<sub>2.5</sub>-exposed mice.** (A) The change of body weight of mice during treatment. *n* = 15 in each group. (B) Calculation of blood glucose. *n* = 15 in each group. (C) MBP of mice from week 1 to week 24. *n* = 15 in each group. (D) H&E staining of lung tissue (up panel) and heart tissue (down panel) sections. *n* = 6 in each group. Scale bar was 200  $\mu$ m for the images in the up panels of lung and heart. (E) Total cell number and (F) protein concentrations in BALF were measured. *n* = 8 in each group. (G) Serum CK and (H) LDH levels were determined. *n* = 8 in each group. Data were expressed as the mean  $\pm$  SEM. \**P* < 0.05 and \*\**P* < 0.01.



significantly greater in *Nrf2*<sup>-/-</sup> mice, as evidenced by the further increased left ventricular internal diameter during diastole (LVIDd) and LV internal diameter during systole (LVIDs), as well as the decreased LV fractional shortening (LVFS%) and LV ejection fraction (LVEF%) (Figure 2D). As shown in Figure 2E and 2F, *Nrf2*<sup>-/-</sup> markedly promoted the fibrotic area in cardiac sections from PM<sub>2.5</sub>-exposed mice compared to *Nrf2*<sup>+/+</sup> group. Consistently, PM<sub>2.5</sub>-induced increase of *Colla1*,  $\alpha$ -SMA, FN and TGF $\beta$ 1 was further promoted in the *Nrf2*<sup>-/-</sup> mice by RT-qPCR analysis (Figure 2G). Exposure to PM<sub>2.5</sub> increased the TGF $\beta$ 1, p-Smad2 and p-Smad3 protein levels in the hearts of *Nrf2*<sup>+/+</sup> mice; however, these changes were significantly greater in *Nrf2*<sup>-/-</sup> mice (Figure 2H). Together, these findings suggested that the cardiac dysfunction and fibrosis in the *Nrf2*<sup>-/-</sup> mice were more serious than those in the *Nrf2*<sup>+/+</sup> mice after PM<sub>2.5</sub> exposure.

### **Nrf2 knockout promotes PM<sub>2.5</sub>-induced oxidative stress in hart tissues**

As shown in Figure 3A, long term PM<sub>2.5</sub> exposure resulted in a significant reduction in serum superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) of *Nrf2*<sup>+/+</sup> mice, which were further decreased in PM<sub>2.5</sub>-induced mice with the loss of *Nrf2*. However, *Nrf2*<sup>-/-</sup> mice developed more malondialdehyde (MDA) and inducible nitric oxide synthase (iNOS) levels in serum compared to *Nrf2*<sup>+/+</sup> mice after PM<sub>2.5</sub> exposure. In addition, *Nrf2*<sup>-/-</sup> mice exhibited lower cardiac SOD activity than that of the *Nrf2*<sup>+/+</sup> mice exposed to PM<sub>2.5</sub>. Additionally, long term PM<sub>2.5</sub> exposure led to greater oxidative stress in hearts of *Nrf2*<sup>-/-</sup> mice than in hearts of *Nrf2*<sup>+/+</sup> mice, as evidenced by higher 3'-Nitrotyrosine (3'-NT), 4-hydroxy-2-nonenal (4-HNE) and 8-hydroxy 2 deoxyguanosine (8-OHdG) levels (Figure 3B). Immunohistochemical (IHC) staining further demonstrated that PM<sub>2.5</sub>-induced 8-OHdG expression in cardiac sections was further accelerated in *Nrf2*<sup>-/-</sup> mice (Figure 3C and 3D). Furthermore, *Nrf2*<sup>-/-</sup> mice showed lower SOD1 and SOD2 mRNA levels, and higher NOX2 and NOX4 levels than *Nrf2*<sup>+/+</sup> mice after PM<sub>2.5</sub> exposure (Figure 3E). Western blot analysis suggested that the expression of HO1, NQO1 and GCLM was lower, whereas Keap1 expression was higher in *Nrf2*<sup>-/-</sup> hearts than in *Nrf2*<sup>+/+</sup> hearts (Figure 3F and 3G). Herein, *Nrf2* knockout exacerbated PM<sub>2.5</sub>-induced cardiac oxidative stress.


### **Nrf2 deficiency enhances cardiac inflammation, RIPK3 expression and mitochondrial disorder in PM<sub>2.5</sub>-exposed mice**

ELISA analysis indicated that the serum and heart concentrations of TNF- $\alpha$ , IL-1 $\beta$  and IL-6 in *Nrf2*<sup>-/-</sup> mice were significantly higher than those in the *Nrf2*<sup>+/+</sup> mice


after PM<sub>2.5</sub> exposure (Figure 4A and 4B). We next found that *Nrf2*<sup>-/-</sup> mice developed higher expression of p-IkBa and p-NF- $\kappa$ B in hearts compared to the *Nrf2*<sup>+/+</sup> mice in response to PM<sub>2.5</sub> (Figure 4C). According to previous studies, RIPK3 plays a significant role in regulating oxidative stress, fibrosis and inflammation in various types of tissues under different stimuli [23–27]. Subsequently, we found that cardiac RIPK3 expression was markedly up-regulated by PM<sub>2.5</sub> exposure and was further elevated in the *Nrf2*<sup>-/-</sup> mice by RT-qPCR and western blot analysis (Figure 4D and 4E). IHC staining demonstrated that the *Nrf2*<sup>-/-</sup> mice exhibited higher expression of RIPK3 and p-NF- $\kappa$ B in cardiac tissue sections than the *Nrf2*<sup>+/+</sup> mice after 24 weeks under PM<sub>2.5</sub> exposure (Figure 4F). Mitochondrial dysfunction shows essential role in meditating ROS production, fibrotic response and inflammatory response during the progression of cardiomyopathy [22, 29, 30]. Then, as displayed in Figure 4G–4I, PM<sub>2.5</sub> resulted in significant decreases in adenosine triphosphate (ATP) and cardiac fiber OXPHOS capacity (respiration rate at saturating levels of ADP) with complex I-linked substrates, which were further down-regulated in *Nrf2*<sup>-/-</sup> mice. In contrast, increased mtDNA levels, a marker of mitochondrial injury, were observed in the hearts of *Nrf2*<sup>+/+</sup> mice after PM<sub>2.5</sub> exposure, and this effect was greater in *Nrf2*<sup>-/-</sup> mice with exposure to PM<sub>2.5</sub>. Subsequently, mitochondrial dysfunction-associated genes were measured by RT-qPCR analysis. *Nrf2*<sup>-/-</sup> mice showed higher levels of *Fis1*, *Drp1*, *Mid51* and *Mid49* in cardiac samples compared to those from *Nrf2*<sup>+/+</sup> mice after PM<sub>2.5</sub> exposure; however, *MFN1*, *MFN2* and *Opa1* mRNA levels reduced by PM<sub>2.5</sub> were further down-regulated by *Nrf2*<sup>-/-</sup> (Figure 4J). Together, the results above demonstrated that *Nrf2* deficiency could promote cardiac inflammation, RIPK3 expression and mitochondrial disorder in PM<sub>2.5</sub>-exposed mice.

### **Nrf2 loss promotes autophagy initiation and disorder of glucose metabolism in hearts of PM<sub>2.5</sub>-challenged mice**

Autophagy plays a critical role in regulating the progression of mitochondrial disorder [31]. In addition, PM<sub>2.5</sub> long-term exposure was reported to induce autophagy in human lung epithelial A549 cells, which was also associated with the induction of oxidative stress [32]. To further explore the molecular mechanisms, we then assessed the protein expression levels of signals involved in autophagy regulation including Beclin1/Atg6, Vps34, LC3B and ATG5. Beclin1/Atg6 forms a complex with Vps34, and this complex is involved in the initiation of autophagy and the formation of autophagosomes [33]. Furthermore, LC3B-II and ATG5 are essential hallmarks of autophagosomes [34]. Western blot results demonstrated that long-term exposure of PM<sub>2.5</sub> caused higher



**Figure 2. Nrf2 deletion accelerates cardiac dysfunction and fibrosis in PM<sub>2.5</sub>-exposed mice.** (A) Measurements of heart weight. n = 15 in each group. (B) Calculation of the ratio of heart weight to body weight. n = 15 in each group. (C) RT-qPCR analysis of ANP and BNP mRNA levels in heart samples. n = 6 in each group. (D) Cardiac function was analyzed by echocardiography, and LVIDd, LVIDs, LVFS% and LVEF% were quantified. n = 15 in each group. (E) Masson's trichrome staining (up panel) and Sirius Red staining (down panel) of cardiac sections. Scale bar was 100 μm. n = 6 in each group. (F) Calculation of fibrotic area following Masson's trichrome and Sirius Red staining. n = 6 in each group. (G) RT-qPCR analysis of Col1a1, α-SMA, FN and TGFβ1 mRNA levels in heart samples. n = 6 in each group. (H) Western blot analysis of TGFβ1, p-Smad2 and p-Smad3 protein levels in heart tissues. n = 6 in each group. Data were expressed as the mean ± SEM. \**P* < 0.05 and \*\**P* < 0.01; ns, no significant difference.




**Figure 3. Nrf2 knockout promotes PM<sub>2.5</sub>-induced oxidative stress in heart tissues.** (A) SOD, GSH-Px, MDA and iNOS levels in serum of mice were measured. n = 8 in each group. (B) SOD, 3'-NT, 4-HNE and 8-OHdG levels in cardiac samples were determined. n = 8 in each group. (C, D) IHC staining of 8-OHdG and the quantification of its relative expression were exhibited. Scale bar was 100  $\mu$ m. n = 6 in each group. (E) RT-qPCR analysis of SOD1, SOD2, NOX2 and NOX4 mRNA levels in heart samples. n = 6 in each group. (F, G) Western blot analysis of HO1, NQO1, GCLM and Keap1 protein expression in heart tissues. n = 6 in each group. Data were expressed as the mean  $\pm$  SEM. \**P* < 0.05 and \*\**P* < 0.01.



expression of Beclin1, Vps34, LC3B-II and ATG5 in cardiac tissues of mice, and of note, these effects were markedly accelerated when Nrf2 was knocked out (Figure 5A and 5B). Therefore, we demonstrated that PM<sub>2.5</sub>-induced cardiac injury was associated with the initiation of autophagy.

Moreover, mitochondrial dysfunction was suggested to be involved in the progression of glucose metabolism disorder under different stresses [35, 36]. To further gain insight into the effect of PM<sub>2.5</sub> on cardiac glucose metabolism, we analyzed the mRNA expression levels of glucose metabolism-related signals. Compared with

the FA group, PM<sub>2.5</sub> treatment led to slight decreases in the expression of GCK, PK, mitochondrial enzyme SDH and hexokinase 1 (HK1) [37–39]; however, gluconeogenesis genes including glucose-6 phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) were up-regulated by PM<sub>2.5</sub> [40]. Of note, these effects were markedly exacerbated in mice with Nrf2 deficiency following long-term exposure of PM<sub>2.5</sub> (Figure 6A–6D). These findings demonstrated that PM<sub>2.5</sub> challenge mediated gene expression levels of the key rate-limiting enzyme involved in glucose metabolism, which was associated with Nrf2 expression.




**Figure 4. Nrf2 deficiency enhances cardiac inflammation, RIPK3 expression and mitochondrial disorder in PM<sub>2.5</sub>-exposed mice.** ELISA analysis of TNF- $\alpha$ , IL-1 $\beta$  and IL-6 in (A) serum and (B) heart tissue samples. n = 8 in each group. (C) Western blot analysis of p-I $\kappa$ B $\alpha$  and p-NF- $\kappa$ B in heart tissues. n = 6 in each group. (D) RT-qPCR and (E) western blot analysis of RIPK3 in heart tissues from each group of mice. n = 6 in each group. (F) Representative images for IHC staining of p-NF- $\kappa$ B and RIPK3 in the cardiac sections, and the quantified results of p-NF- $\kappa$ B and RIPK3 were showed. Scale bar was 100  $\mu$ m. n = 6 in each group. (G) ATP production in hearts. n = 8 in each group. (H) Content of mtDNA was calculated through the ratio of Cox1 to cyclophilin A. n = 8 in each group. (I) Evaluation of complex I respiration rate. n = 8 in each group. (J) RT-qPCR analysis of mitochondrial function-associated genes, including Fis1, Drp1, Mid51, Mid49, MFN1, MFN2 and Opa1, in heart tissues. n = 6 in each group. Data were expressed as the mean  $\pm$  SEM. \**P* < 0.05 and \*\**P* < 0.01.

## Nrf2-regulated ROS production and RIPK3 expression is involved in PM<sub>2.5</sub>-induced oxidative stress, fibrosis and inflammation *in vitro*

To further explore the effects of Nrf2 on cardiac injury, *in vitro* experiments were performed. First, the cell viability was investigated using MTT analysis. The results suggested that PM<sub>2.5</sub> dose-dependently reduced the cell viability of cardiomyocytes isolated from Nrf2<sup>+/+</sup> mice; however, these effects were further exacerbated in cardiomyocytes isolated from Nrf2<sup>-/-</sup> mice, demonstrating the pivotal role of Nrf2 in sustaining cell survival rate (Figure 7A). Considering the essential role of oxidative stress and RIPK3 in Nrf2-regulated cardiomyopathy induced by PM<sub>2.5</sub>, ROS scavenger N-acetyl-L-cysteine (NAC), HO1 activator cobalt protoporphyrin IX (CoPPiX) and RIPK3 siRNA (si-RIPK3) were subjected to PM<sub>2.5</sub>-incubated cardiomyocytes isolated from Nrf2<sup>-/-</sup> mice. The successful transfection efficacy of si-RIPK3 in cardiomyocytes was confirmed by western blot analysis (Supplementary Figure 1B). As shown in Figure 7B, PM<sub>2.5</sub>-induced cellular ROS was further elevated in Nrf2<sup>-/-</sup> cardiomyocytes. Of note, we found that pre-treatment of NAC, CoPPiX or si-RIPK3 markedly reduced Nrf2<sup>-/-</sup>-elevated ROS generation in PM<sub>2.5</sub>-incubated cardiomyocytes. Inversely, PM<sub>2.5</sub>-decreased concentration of antioxidants, including SOD, glutathione (GSH) and GPX was further reduced by Nrf2<sup>-/-</sup>, and this effect was rescued

in response to NAC, CoPPiX or si-RIPK3. HO1, NQO1 and GCLM expression levels were inactivated by PM<sub>2.5</sub>, and were further reduced by Nrf2 knockout. However, addition of NAC, CoPPiX or transfection with si-RIPK3 restored the HO1, NQO1 and GCLM expression despite the Nrf2<sup>-/-</sup>. In contrast, NAC, CoPPiX or si-RIPK3 significantly abrogated Nrf2<sup>-/-</sup>-promoted Keap1 expression in PM<sub>2.5</sub>-incubated cardiomyocytes (Figure 7C). The expression of TGFβ1 and α-SMA was increased in PM<sub>2.5</sub>-treated cells and was further aggravated in response to Nrf2<sup>-/-</sup>. However, blockade of the ROS and RIPK3, or promotion of HO1 significantly abolished the TGFβ1 and α-SMA expression despite Nrf2 deficiency (Figure 7D). Similarly, the inflammatory factors, including TNF-α and IL-1β, were also up-regulated in PM<sub>2.5</sub>-incubated cells, and were accelerated in response to Nrf2 knockout. These effects were significantly nullified by NAC, CoPPiX or si-RIPK3 (Figure 7E). Consistent with the change of TNF-α and IL-1β, similar results were detected in the expression of p-IκBα and p-NF-κB (Figure 7F). Moreover, the content of LDH was increased in PM<sub>2.5</sub>-treated cardiomyocytes, indicative of the breakage of cell membranes due to cell death. Nrf2<sup>-/-</sup> further enhanced the LDH release, and this effect was reversed by NAC, CoPPiX or si-RIPK3 (Figure 7G). Herein, Nrf2-regulated ROS production and RIPK3 expression was implicated in PM<sub>2.5</sub>-induced oxidative stress, fibrosis and inflammation.




**Figure 5. Nrf2 loss promotes autophagy initiation in PM<sub>2.5</sub>-challenged mice.** (A) Representative images of western blotting bands for Beclin1, Vps34, LC3B and ATG5 in cardiac tissues. (B) Relative quantification of these molecules by western blot analysis. n = 6 in each group. Data were expressed as the mean ± SEM. \*P < 0.05.



## Nrf2 modulates RIPK3 expression to regulate mitochondrial disorder in PM<sub>2.5</sub>-exposed cardiomyocytes

RIPK3 has been reported to be involved in the alteration of mitochondrial disorder [27]. Subsequently, RIPK3 expression was further inhibited by addition of GSK872, a RIPK3 inhibitor (Figure 8A). As shown in Figure 8B and 8C, the mitochondrial potential and ATP were significantly reduced by PM<sub>2.5</sub> treatment. However, RIPK3 knockdown and inhibition by GSK872 rescued the mitochondrial potential and ATP levels in PM<sub>2.5</sub>-treated cardiomyocytes despite Nrf2 knockout. Besides, the opening rate of mitochondrial permeability transition pore (mPTP) was significantly up-regulated in PM<sub>2.5</sub>-treated cells and was further promoted by Nrf2 knockout, which was, however, dramatically decreased by the suppression of RIPK3 (Figure 8D). Then, RT-qPCR analysis suggested that mitochondrial disorder was markedly induced in cardiomyocytes in response to PM<sub>2.5</sub>. However, the loss of Nrf2 promoted PM<sub>2.5</sub>-induced expression of fission protein 1 (Fis1), dynamin-related protein 1 (Drp1), mitochondrial dynamics protein of 51 (Mid51) and mitochondrial dynamics protein of 49 (Mid49), and these effects were considerably blocked by

RIPK3 suppression. In contrast, si-RIPK3 or GSK872 pre-treatment significantly restored the expression of mitofusin-1 (MFN1), MFN2 and optic atrophy 1 (Opa1) in PM<sub>2.5</sub>-incubated cardiomyocytes with Nrf2 deficiency when compared to Nrf2<sup>-/-</sup> cardiomyocytes only treated with PM<sub>2.5</sub> (Figure 8E). To further determine the effect of RIPK3 on mitochondrial respiratory chain complexes, mitochondrial fractions were isolated from Nrf2<sup>+/+</sup> and Nrf2<sup>-/-</sup> cardiomyocytes following PM<sub>2.5</sub> exposure. Western blots demonstrated that PM<sub>2.5</sub> treatment significantly reduced the function of mitochondrial complex I, -II -III, and -IV, as evidenced by the reduced expression of NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8 (NDUFB8), succinate dehydrogenase subunit B (SDHB), ubiquinol cytochrome c oxidoreductase core protein (UQCRC1) and mitochondrial cytochrome c oxidase subunit 1 (MTCO1), respectively [41, 42]. These effects were further accelerated by the knockout of Nrf2 in PM<sub>2.5</sub>-incubated cardiomyocytes, but RIPK3 inhibition significantly rescued the expression of these signals (Figure 8F and 8G). Taken together, these results demonstrated that Nrf2<sup>-/-</sup>-enhanced mitochondrial dysfunction could be improved by RIPK3 suppression in PM<sub>2.5</sub>-exposed cardiomyocytes.




**Figure 6. Nrf2 knockout enhances abnormal glucose metabolism in hearts of PM<sub>2.5</sub>-exposed mice.** (A) GCK, (B) PK and (C) SDH activities in hearts of mice were measured. n = 7 or 8 in each group. (D) RT-qPCR was used to measure GCK, PK, HK1, G6Pase and PEPCK mRNA levels in hearts of mice. n = 6 in each group. Data were expressed as the mean ± SEM. \*P < 0.05; ns, no significant difference.

## Promoting Nrf2 expression alleviates PM<sub>2.5</sub>-induced cardiomyopathy

Finally, RT-qPCR and western blot analysis suggested that Nrf2 mRNA and protein levels in cardiac samples were up-regulated in mice exposed to PM<sub>2.5</sub> during the beginning two months, and then were down-regulated especially at the end of PM<sub>2.5</sub> treatment (Figure 9A and

9B). Subsequently, dimethyl fumarate (DMF), as a critical Nrf2 activator [43, 44], was administered to mice with or without PM<sub>2.5</sub> exposure to further investigate the effects of Nrf2 on PM<sub>2.5</sub>-induced cardiomyopathy. As shown in Figure 9C and 9D, PM<sub>2.5</sub>-reduced expression of Nrf2 in heart tissues was markedly rescued by DMF. H&E staining demonstrated that DMF supplementation improved PM<sub>2.5</sub>-induced




**Figure 7. Nrf2-regulated ROS production and RIPK3 expression is involved in PM<sub>2.5</sub>-induced oxidative stress, fibrosis and inflammation *in vitro*.** (A) Cardiomyocytes isolated from Nrf2<sup>+/+</sup> or Nrf2<sup>-/-</sup> mice were treated with the indicated concentrations (0, 5, 12.5, 25, 50, 100 and 200 μg/ml) of PM<sub>2.5</sub> for 24 h. Then, all cells were harvested for cell viability measurement using MTT analysis. n = 8 in each group. (B–G) Cardiomyocytes isolated from Nrf2<sup>+/+</sup> or Nrf2<sup>-/-</sup> mice were pre-treated with NAC (5 mM) or CoPPiX (15 μM) for 2 h, or transfected with si-RIPK3 for 24 h. Then, all cells were incubated with PM<sub>2.5</sub> (100 μg/ml) for another 24 h. After treatments above, all cells were collected for further calculation. (B) Intracellular calculation of ROS production, SOD activity, GSH and GPX levels. n = 8 in each group. (C) Western blot analysis of HO1, NQO1, GCLM and Keap1 protein expression in cells. n = 6 in each group. (D) Western blot analysis of TGFβ1 and α-SMA in cells. n = 6 in each group. (E) RT-qPCR analysis of TNF-α and IL-1β in cells. (F) Western blot analysis of p-IκBα and p-NF-κB in cells. n = 6 in each group. (G) LDH release in cells. n = 8 in each group. Data were expressed as the mean ± SEM. \*P < 0.05 and \*\*P < 0.01.

change of cardiac histopathology (Figure 9E). In addition, cardiac RIPK3 expression induced by PM<sub>2.5</sub> was significantly decreased by DMF following IHC and western blot analysis (Figure 9E and 9F). DMF treatment improved PM<sub>2.5</sub>-induced cardiac dysfunction, as evidenced by the increased LVFS% and LVEF% (Figure 9G). Then, significantly up-regulated SOD activity and down-regulated 4-HNE levels were detected in hearts of DMF-treated mice after PM<sub>2.5</sub> exposure (Figure 9H). As expected, a significant decrease in HO1, NQO1 and GCLM was observed in hearts of PM<sub>2.5</sub>-exposed mice, while Keap1 was increased. These effects were markedly reversed by DMF (Figure 9I). As shown in Figure 9J and 9K, DMF administration dramatically reduced

PM<sub>2.5</sub>-induced expression of cardiac Colla1,  $\alpha$ -SMA, FN, TGF $\beta$ 1, TNF- $\alpha$  and IL-1 $\beta$  compared to PM<sub>2.5</sub> group. Within expectation, DMF treatment evidently alleviated the expression of TGF $\beta$ 1 and p-NF- $\kappa$ B in hearts of mice receiving PM<sub>2.5</sub> (Figure 9L). The *in vivo* results above indicated that promoting Nrf2 expression could alleviate PM<sub>2.5</sub>-induced cardiomyopathy by preventing RIPK3 expression, oxidative stress, fibrosis and inflammation.

## DISCUSSION

Epidemiologic studies have reported that PM<sub>2.5</sub> pollution is highly associated with cardiovascular diseases, such as stroke, ischemia, arrhythmia and heart




**Figure 8. Nrf2 modulates RIPK3 expression to regulate mitochondrial disorder in PM<sub>2.5</sub>-exposed cardiomyocytes.** (A) Cardiomyocytes were treated with the indicated concentrations of GSK872 (0, 1.25, 2.5 and 5  $\mu$ M) for 2 h, followed by western blot analysis of RIPK3.  $n = 6$  in each group. (B–G) Cardiomyocytes isolated from Nrf2<sup>+/+</sup> or Nrf2<sup>-/-</sup> mice were pre-treated with GSK872 (15  $\mu$ M) for 2 h, or transfected with si-RIPK3 for 24 h. Then, all cells were exposed to PM<sub>2.5</sub> (100  $\mu$ g/ml) for another 24 h. After treatments above, all cells were collected for further studies. (B) Mitochondrial potential results by JC-1 analysis.  $n = 8$  in each group. (C) Intracellular ATP levels were measured.  $n = 8$  in each group. (D) Results of mPTP opening in cells.  $n = 8$  in each group. (E) RT-qPCR analysis of Fis1, Drp1, Mid51, Mid49, MFN1, MFN2 and Opa1 in cells.  $n = 6$  in each group. (F, G) Western blot analysis of NDUFB8, SDHB, UQCRC1 and MTCO1 in the mitochondrial fractions.  $n = 6$  in each group. Data were expressed as the mean  $\pm$  SEM. \* $P < 0.05$  and \*\* $P < 0.01$ .



failure [1–4]. Nrf2 is a key transcription factor that regulates antioxidant defense [45], and Nrf2 could protect against diverse PM<sub>2.5</sub> components-induced mitochondrial oxidative damage in lung cells [46]. Here, we demonstrated three major new findings. On the one, our results indicated that long term PM<sub>2.5</sub>

exposure led to more severe cardiac dysfunction and injury in Nrf2<sup>-/-</sup> mice than that in the Nrf2<sup>+/+</sup> mice. On the other, the accelerated fibrosis, oxidative stress and inflammation in PM<sub>2.5</sub>-treated Nrf2<sup>-/-</sup> mice were significantly associated with the abnormal expression of RIPK3 and RIPK3-induced mitochondrial disorder.



**Figure 9. Promoting Nrf2 expression alleviates PM<sub>2.5</sub>-induced cardiomyopathy.** (A) RT-qPCR and (B) western blot analysis of Nrf2 in heart tissues from Nrf2<sup>+/+</sup> mice at the indicated time points. n = 6 in each group. (C) RT-qPCR and (D) western blot analysis of Nrf2 in heart tissues from Nrf2<sup>+/+</sup> mice treated with or without DMF. n = 6 in each group. (E) Representative images of H&E staining and RIPK3 staining of cardiac sections from the indicated groups of mice were displayed, and the relative expression of RIPK3 was quantified by IHC. n = 6 in each group. (F) Western blot analysis of RIPK3 in heart tissues. n = 6 in each group. (G) Cardiac function was analyzed by echocardiography. LVFS% and LVEF% were quantified. n = 10 in each group. (H) Cardiac SOD and 4-HNE levels were measured. n = 8 in each group. (I) Western blot analysis of HO1, NQO1, GCLM and Keap1 protein expression in heart tissues. n = 6 in each group. (J) RT-qPCR analysis of Col1a1,  $\alpha$ -SMA, FN and TGF $\beta$ 1 mRNA levels in heart samples. n = 6 in each group. (K) ELISA analysis of TNF- $\alpha$  and IL-1 $\beta$  in heart tissues. n = 8 in each group. (L) Western blot analysis of TGF $\beta$ 1 and p-NF- $\kappa$ B in heart tissues. n = 6 in each group. Data were expressed as the mean  $\pm$  SEM. \**P* < 0.05 and \*\**P* < 0.01; ns, no significant difference.

Finally, we demonstrated that promoting Nrf2 expression by its activator of DMF considerably alleviated PM<sub>2.5</sub>-induced cardiac injury through reducing RIPK3 expression, oxidative stress, fibrosis and inflammatory response. As far as we know, it was the first study that Nrf2 exhibited a significant protective role against PM<sub>2.5</sub>-induced cardiomyopathy through suppressing collagen accumulation, oxidative stress and inflammation regulated by RIPK3, as well as the improvement of autophagy and glucose metabolism in hearts.

Growing studies have indicated that PM<sub>2.5</sub> contains very complex toxic chemical compositions. The lung tissue is a primary biological target for injury arising from inhalation exposure to PM<sub>2.5</sub>. Airborne pollutants could be released into the pulmonary surfactant and attach to lung epithelial cells, resulting in pulmonary damage [47, 48]. As reported before, therapeutic strategy to induce Nrf2 expression is effective for preventing PM<sub>2.5</sub>-induced lung injury [49]. In our present study, we confirmed that PM<sub>2.5</sub> exposure led to significant lung injury, along with high cell influx and protein concentration in the extracted BALF, which were however, further accelerated in Nrf2<sup>-/-</sup> mice after PM<sub>2.5</sub> exposure. Our previous studies also revealed the critical role of Nrf2 in preventing hypothalamus inflammation, renal injury and liver damage in rodent animals under PM<sub>2.5</sub> stimuli [15–17]. These findings demonstrated that Nrf2 might be connected to PM<sub>2.5</sub> particles-induced heart injury. The heart is another important target organ of PM<sub>2.5</sub> exposure. The direct acute influences of PM<sub>2.5</sub> on the myocardium involve ROS production, spontaneous arrhythmias and alterations in myocardial blood [50]. In this study, we elucidated that exposure to PM<sub>2.5</sub> for 6 months led to moderate physiological changes, histopathological changes, collagen accumulation, oxidative stress, inflammatory response and mitochondrial dysfunction in hearts of Nrf2<sup>+/+</sup> mice. However, these effects were markedly exacerbated by the deficiency of Nrf2. Autophagy is an evolutionarily conserved lysosomal catabolic mechanism involved in degradation of damaged organelles and long-lived proteins in response to unfavorable conditions [31, 33, 34, 51]. *In vivo* evidence showed that excessive autophagy was involved in testicular blood-testis barrier (BTB) damage and toxicity of rats after developmental exposure to the air pollution PM<sub>2.5</sub>, which could be mediated by the increasing ROS [52]. In addition, the PM<sub>2.5</sub>-induced oxidative stress probably plays a key role in autophagy in human lung epithelial A549 cells, which may contribute to PM<sub>2.5</sub>-induced impairment of pulmonary function [53]. In addition, Nrf2 signaling has been demonstrated to control autophagy under various stresses [54, 55]. Similarly, here we found that long-term PM<sub>2.5</sub> led to the initiation of autophagy, as

evidenced by the slightly up-regulated expression of Beclin1, Vps34 and LC3B-II; however, these effects were markedly enhanced by Nrf2 knockout. Increasing studies have reported that mitochondrial dysfunction is associated with glucose metabolism. For instance, the impaired insulin-induced abnormal glucose metabolism was attributed to mitochondrial fission in skeletal muscle [56]. Our previous studies confirmed that PM<sub>2.5</sub> exposure led to insulin resistance in liver tissues, contributing to non-alcoholic fatty liver disease with significantly increased blood glucose levels [17]. Here, we found that PM<sub>2.5</sub> treatment led to abnormal glucose metabolism in cardiac samples, as evidenced by the decreased expression of glycolytic enzymes, such as GCK, PK and HK1, along with the increased gluconeogenic enzymes G6Pase and PEPCK [37–40]. Of note, these effects were markedly aggravated when Nrf2 was deleted. Numerous studies have implied the essential of Nrf2 in maintaining glycometabolism partly associated with the mitochondrial function [57, 58]. Therefore, we hypothesized that PM<sub>2.5</sub>-induced cardiac injury was related to the degradation of glucose metabolism regulated by Nrf2. Furthermore, promoting Nrf2 expression by DMF could alleviate PM<sub>2.5</sub>-induced cardiomyopathy in the wild type mice. It has been suggested that genetic impairments of Nrf2 could result in metabolic disturbance in cardiovascular systems under stress conditions [59]. Thereby, our results also supported the notion that prolonged PM<sub>2.5</sub> exposure elevates adverse influences to individuals with underlying cardiometabolic diseases.

The adverse effects of PM<sub>2.5</sub> exposure on cardiovascular diseases and pulmonary system are well indicated [2, 3, 49, 50]. These harmful effects triggered by PM<sub>2.5</sub> might be involved in the oxidative stress mechanism, which is also known to play an essential role in the pathogenesis of cardiac fibrosis and inflammation [60, 61]. Thus, PM<sub>2.5</sub> exposure might be associated with collagen accumulation and inflammatory response in hearts through the oxidative stress mechanism. Nrf2 plays a critical role in the improvement of various inflammatory- and oxidative stress-induced diseases [62, 63]. Our study suggested that exposure to the high level of real-world ambient PM<sub>2.5</sub> for 6 months significantly increased fibrosis in hearts of Nrf2<sup>+/+</sup> mice, as evidenced by the up-regulation of Colla1,  $\alpha$ -SMA, FN and TGF $\beta$ 1. Colla1 is one of the major collagen proteins of the extracellular matrix in tissues. FN and  $\alpha$ -SMA are characterized by fibrogenesis [64]. TGF $\beta$ 1 is central to the pro-fibrotic switch, activation of myofibroblasts and matrix accumulation [65]. Previous studies also showed that PM<sub>2.5</sub> exposure alone could cause mild hepatic fibrosis and activation of the TGF $\beta$ -Smad3 signaling pathway [66, 67]. Consistently, our western blot analysis suggested that

PM<sub>2.5</sub> exposure led to a significant increase of TGFβ1, p-Smad2 and p-Smad3 in heart tissues. On the other, overproduction of pro-inflammatory cytokines regulated by IκBα/NF-κB signaling also contributes to the cytotoxicity of PM<sub>2.5</sub> [15, 17, 68, 69]. Thereby, the increased levels of serum or heart TNFα, IL-1β and IL-6, and the up-regulated expression of p-IκBα and p-NF-κB in hearts from PM<sub>2.5</sub>-exposed Nrf2<sup>+/+</sup> mice provided an alternate essential mechanism for the cardiac dysfunction observed herein. Interestingly, PM<sub>2.5</sub>-induced fibrosis and inflammatory response were further accelerated by the Nrf2<sup>-/-</sup>.

Transcription factor Nrf2 is a master regulator of numerous cytoprotective genes, which has been a potential target for the treatment of a variety of cardiovascular diseases [10, 11]. Nrf2 is anchored in the cytoplasm where it binds to Keap1 under normal condition. However, Nrf2 could translocate into the nucleus and then activate its target genes through an antioxidant-response element (ARE). Nrf2 thus can negatively modulate the dissociation and polymerization with Keap1, subsequently adjust the expression of some anti-oxidative genes or enzymes against oxidative stress, such as SOD, HO1, NQO1, GSH and GCLM [9, 12–14]. In our study, we found that PM<sub>2.5</sub> exposure caused significant oxidative stress in heart tissues, as evidenced by the reduction of SOD, HO1, NQO1, GSH and GCLM. In contrast, subsequent products or hallmarks for oxidative stress, including MDA, 4-HNE, 3'-NT, 8-OHdG, NOX2 and NOX4 [16, 70, 71], were found to be significantly up-regulated by PM<sub>2.5</sub> exposure. As expected, Nrf2 knockout further accelerated PM<sub>2.5</sub>-triggered oxidative stress in cardiac samples, which contributed to the collagen accumulation and inflammatory response. In addition, our *in vitro* experiments confirmed the protective role of Nrf2 against PM<sub>2.5</sub>-induced ROS generation, fibrosis and inflammation. Importantly, we found that preventing ROS production by NAC or elevating HO1 activation by CoPPiX could significantly alleviate Nrf2<sup>-/-</sup>-promoted oxidative stress, fibrosis and inflammation in cardiomyocyte stimulated by PM<sub>2.5</sub>. Therefore, Nrf2-regulated oxidative stress played a critical role in PM<sub>2.5</sub>-induced cardiac injury through modulating fibrosis and inflammation.

Our previous study showed that RIPK3-mediated oxidative stress and inflammation were involved in metabolic stress-induced hepatic injury associated with Nrf2 signaling [26]. Recently, RIPK3 was suggested to promote necroptosis in cardiac ischemia-reperfusion injury through activating ROS production [25]. A strong evidence reported that RIPK3-dependent mitochondrial dysfunction led to compromised kidney tubular epithelial cell function, contributing to acute

kidney injury [27]. RIPK3-dependent signaling results in mitochondrial depolarization and decreases expression of mitochondrial complex subunits in response to endotoxin. Genetic RIPK3 knockout preserves ATP production in cells following lipopolysaccharides stimulation [27]. Furthermore, accumulating evidence demonstrate that changes in mitochondrial dynamics such as structural and functional aberrations in mitochondria have been implicated in cardiovascular diseases, including cardiomyocyte hypertrophy and ischemia-reperfusion injury [72, 73]. Mitochondria could reach a kind of equilibrium between mitochondrial fusion and fission, which are essential for mitochondrial growth, redistribution and maintenance of a healthy mitochondrial function. A significant mechanism of ambient PM<sub>2.5</sub> exposure-induced acute heart injury in rats was attributed to mitochondrial damage [74]. In our study, we also found that PM<sub>2.5</sub> exposure led to a significant expression of RIPK3 in heart tissues, attendant with reduced ATP production and mitochondrial Complex I respiration, while increased mtDNA levels. In addition, mitochondrial fusion is regulated by two mitofusins (MFN1 and MFN2) in outer membrane and Opa1 in inner membrane [75]. Fis1 is also involved in mitochondrial fission through recruiting the cytoplasmic Drp1 into the mitochondrial outer-membrane. Drp1 can punctuate spots on the mitochondrial surface to regulate mitochondrial fission for meeting energy needs [76]. MID49 and MID51, as receptors for the mitochondrial fission protein Drp1, are also crucial mediators of mitochondrial fission and novel targets for cardioprotection [77]. Here, our study also demonstrated that PM<sub>2.5</sub> exposure led to significant up-regulation of Fis1, Drp1, Mid51 and Mid49, and down-regulation of MFN1, MFN2 and Opa1 in heart tissues. These results indicated that long-term PM<sub>2.5</sub> exposure caused mitochondrial injury and dysfunction, which was involved in cardiac injury. As reported, Nrf2 knockout exacerbates frailty and sarcopenia through impairing skeletal muscle mitochondrial biogenesis and dynamics [78]. The function of Nrf2 is inhibited in mitochondria-associated disorders. Nrf2 deletion results in impaired mitochondrial respiration and ATP production [79]. In the present work, we demonstrated that PM<sub>2.5</sub>-induced increase of RIPK3 and mitochondrial disorder was further accelerated in Nrf2<sup>-/-</sup> mice. The *in vitro* experiments suggested that blocking RIPK3 expression could attenuate Nrf2 deletion-enhanced mitochondrial disorder in PM<sub>2.5</sub>-incubated cardiomyocytes, as evidenced by the rescued mitochondrial potential, ATP production and the reduced mPTP opening. As a consequence, mPTP opening causes mitochondrial potential collapse, oxidative phosphorylation attest and ATP undersupply [80]. We also




found that the function of mitochondrial complex I-IV, as proved by the expression of NDUFB8, SDHB, UQCRC1 and MTCO1, respectively [41, 42], were declined in PM<sub>2.5</sub>-stimulated cardiomyocytes in a manner through RIPK3. Thus, Nrf2-regulated mitochondrial dysfunction induced by PM<sub>2.5</sub> was dependent on RIPK3 expression, which further contributed to ROS overproduction, fibrosis and inflammation. However, the role of other mitophagy regulators in PM<sub>2.5</sub>-induced cardiovascular disease requires further investigation.

Previous studies indicated that Nrf2 was significant for the protection against multiple stresses-induced cardiovascular diseases [81, 82]. In the present study, Nrf2 was found to be involved in the protection of PM<sub>2.5</sub>-induced cardiac injury by regulating oxidative stress, fibrosis and inflammation via RIPK3-mediated mitochondrial disorder. To confirm our hypothesis,

Nrf2 activator of DMF, a drug approved for treatment of multiple sclerosis and psoriasis by activating Nrf2-responsive genes [83], was then subjected to mice with PM<sub>2.5</sub> exposure. We found that DMF exhibited beneficial effects in PM<sub>2.5</sub>-induced cardiomyopathy by inhibiting RIPK3 expression, oxidative stress, fibrosis and inflammation via the up-regulation of Nrf2.

In conclusion, our present study indicated that Nrf2 could protect against PM<sub>2.5</sub> exposure-induced cardiac injury through suppressing RIPK3-regulated mitochondrial dysfunction, thereby inhibiting ROS production, collagen accumulation and inflammatory response. Moreover, PM<sub>2.5</sub> exposure-induced oxidative stress was partly attributed to glucose metabolism disorder regulated by Nrf2, contributing to cardiac injury (Figure 10). All these findings may highlight that improving Nrf2 activity is a promising strategy to treat air pollution-induced cardiovascular disease.



**Figure 10. Scheme of the Nrf2-mediated cardiac injury induced by PM<sub>2.5</sub>.** Long-term exposure of PM<sub>2.5</sub> to mice resulted in oxidative stress, fibrosis and inflammation via RIPK3-regulated mitochondrial disorder. In addition, autophagy initiation and dysfunction of glucose metabolism were observed in hearts of PM<sub>2.5</sub>-challenged mice. All these effects induced by PM<sub>2.5</sub> were significantly accelerated by the loss of Nrf2, contributing to the progression of cardiomyopathy eventually.

## MATERIALS AND METHODS

### PM<sub>2.5</sub> sampling preparation

The method for PM<sub>2.5</sub> sampling preparation is in accordance with Ying et al. and Ogino et al. [84, 85] procedures with certain modification. In brief, to collect exposure mass, quartz filter (8 cm × 10 cm, 2500QAT-UP, Pallflex Products, Putnam, CT, USA) was used to continuously and weekly gather PM<sub>2.5</sub> from Yuquan Road, Beijing, China (January-June 2015) at a flow rate of 166 L/min. Ambient PM<sub>2.5</sub> filters were then stored in -80°C until administration. The sampling was treated with anhydrous alcohol and dissolved in pyrogen-free water. Next, the extraction was sonicated for 48 h in ultrasonic box and then concentrated by vacuum freeze-drying. Double-distilled water was then added to freeze-dried product, which was subsequently centrifuged at 5000 rpm. The water-insoluble fraction was suspended in D-Hank's buffer (GIBCO Corporation, Gaithersburg, MD, USA) and vortexed prior to further analysis. The components of PM<sub>2.5</sub> were listed in Supplementary Table 1.

### Ethical approval and animals experimental design

The male, 6-8 weeks of age, weighed  $20 \pm 2$  g, wild type C57BL/6J mice (Nrf2<sup>+/+</sup>) and Nrf2 knockout C57BL/6J mice (Nrf2<sup>-/-</sup>) were purchased from the Jackson Laboratory (Bar Harbor, ME). Prior to the animal experiments, all mice were subjected to adapt to the environment for 1 week. They were housed in a specific pathogen-free (SPF), temperature- and humidity-controlled environment ( $25 \pm 2^\circ\text{C}$ ,  $50 \pm 5\%$  humidity) with a standard light/dark (12h/12h) cycle and free access to food and water in their cages. All procedures were in accordance with the Care and Use of Laboratory Animals, which was published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The Institutional Animal Care and Use Committee at Chongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Biological and Chemical Engineering, Chongqing University of Education (81703527) approved the animal study protocols. After one-week acclimatization, all mice were randomly divided into 5 groups: 1) Nrf2<sup>+/+</sup>/FA group; 2) Nrf2<sup>-/-</sup>/FA group; 3) Nrf2<sup>+/+</sup>/PM<sub>2.5</sub> group; 4) Nrf2<sup>-/-</sup>/PM<sub>2.5</sub> group and 5) Nrf2<sup>+/+</sup>/PM<sub>2.5</sub>+DMF group. Mice were exposed to concentrated PM<sub>2.5</sub> ( $150.1 \pm 2.5 \mu\text{g}/\text{m}^3$ , flow rate of 65 L/min) or filtered air (FA, served as control) for 6 h/day, 5 times a week in a mobile exposure system-HOPE-MED 8052 automatic nose and mouth type inhalation exposure system (Hepu Industry and Trade Co., Ltd., China) according to previous studies [15, 16, 86, 87]. Nrf2<sup>+/+</sup> mice were received intra-

peritoneal injections of dimethyl fumarate (DMF, 25 mg/kg/day) for 6 h, and then treated with PM<sub>2.5</sub>. After PM<sub>2.5</sub> exposure for 24 weeks with or without DMF, all mice were sacrificed for blood collection. Body weight of mice was recorded every week. Blood pressure was measured each week by a noninvasive blood pressure meter (Surgivet, USA). The lung and heart tissue samples were isolated from mice for further analysis. DMF was purchased from Sigma-Aldrich (St. Louis, MO, USA) for animal treatments.

### Cells isolation and culture

Mouse cardiomyocytes were isolated from the Nrf2<sup>+/+</sup> or Nrf2<sup>-/-</sup> mice as previously indicated [88, 89]. In brief, hearts from mice were mounted onto a temperature-controlled (37°C) system. After perfusion with a modified Tyrode's solution (Sigma Aldrich), the heart was digested using a Ca<sup>2+</sup>-free Krebs Henseleit-bicarbonate (KHB) buffer supplemented with liberase blendzyme 4 (Roche, Norway) for 20 min. The modified Tyrode solution was gassed with 5% CO<sub>2</sub>. Then, the digested heart was removed from the cannula and the left ventricle was cut into small pieces in the modified Tyrode's solution. Heart tissue pieces were gently agitated, and then pellet of cells was resuspended. A yield of 65% viable rod-shaped cardiomyocytes with clear sarcomere striations was acquired. Only rod-shaped myocytes with clear edges were chose for *in vitro* studies. Control and RIPK3-specific siRNAs were synthesized and purchased from Shanghai Generay Biotech (Shanghai, China) and transfected into cells using Lipofectamine® 3000 (Invitrogen, USA) following the manufacturer's protocol. HO1 activator of CoPPiX, and ROS scavenger of NAC were purchased from Sigma-Aldrich. RIPK3 inhibitor of GSK872 (#HY-101872) was purchased from MedChemExpress (USA) to suppress RIPK3 expression.

### Biochemical analysis

Blood glucose levels were calculated by glucometer (5D-1, ACCU-CHEK, China) every month. The concentration of CK, LDH, MDA, SOD, GSH-Px, GSH and iNOS in fresh serum and heart tissues immediately extracted from each group of mice, or cells were measured using the commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions. Glucokinase (GCK), pyruvate kinase (PK) and succinate dehydrogenase (SDH) activities in hearts of mice were measured using the Assay Kit also purchased from Nanjing Jiancheng Bioengineering Institute according to the instruction recommended by the manufacturer. The levels of 4-HNE in hearts were measured using mouse 4-HNE Elisa kit (Shanghai Shuangying Biotech, Shanghai, China) according to the manufacturer's instructions. The 3'-NT and 8-OHdG in

cardiac samples were measured using commercial kits purchased from Abcam (USA) strictly according to the manufacturer's instructions. Serum levels of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ , #MTA00B), interleukin 1 $\beta$  (IL-1 $\beta$ , #MLB00C) and IL-6 (#M6000B) were measured using enzyme-linked immunosorbent assay (ELISA) commercial kits (R&D System, USA) according to the manufacturer's instructions.

### **BALF isolation and calculation**

After 6 months of exposure, the mice were anesthetized using pentobarbital sodium (20 mg/kg, iv). Then, BALF was collected by lavaging lungs with 1.0 mL of sterile PBS. The BALF was centrifuged at 1000 rpm for 10 min and then suspended in 100  $\mu$ l of PBS to count the total cell and calculate protein concentration with a Bicinchoninic acid (BCA) protein analysis kit (Thermo Fisher Scientific, USA) according to the manufacturer's protocol.

### **Echocardiography**

At the end of animal experiments, all mice were anesthetized using 2,2,2-Tribromethanol (TBE, 200 mg/kg, MedChemExpress, USA). Cardiac function was then assessed through ECG using an Acuson Sequoia C256 System (Siemens) ultrasound machine. For each animal, LVFS%, LVEF%, LVIDd and LVIDs were measured as previously indicated [90, 91].

### **Isolation of cytosolic and mitochondrial fractions**

Cytosolic and mitochondrial fractions were isolated from cells by a mitochondria/cytosol fraction kit (Biovision, USA) according to the manufacturer's protocols. The cytosolic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and mitochondrial inner membrane protein TIM23 were served as standards for cytosol and mitochondrial protein, respectively [92].

### **Western blots and quantitative real-time PCR (RT-qPCR) analysis**

For western blot analysis, heart tissues and cells were homogenized using 10% (wt/vol) hypotonic buffer (pH 8.0) to yield a homogenate. Bicinchoninic acid (BCA) protein analysis kit (Thermo Fisher Scientific) was used to determine the protein concentration according to its instructions. 20-40  $\mu$ g protein from hearts, cells or mitochondrial fractions was subjected to 10% SDS-Polyacrylamide-Gel-Electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, USA), followed by incubation with primary antibodies (Supplementary Table 2) overnight at 4°C. Then, the membranes were incubated

with corresponding secondary antibodies (Supplementary Table 2) for 1 h at room temperature. The signal was detected using enhanced chemiluminescence (ECL) Detection system (Thermo Fisher Scientific). Each protein expression was analyzed using Image Lab Software (Version 1.4.2b, National Institutes of Health, USA), normalized to GAPDH and expressed as a fold of control.

As for RT-qPCR, total RNA from cardiac tissue samples or cells was extracted using Trizol reagent (Invitrogen, USA) according to the manufacturer's introductions. Total RNA was reverse transcribed using M-MLV-RT system (Promega, USA). The action was performed at 42°C for 1 h and terminated via deactivation of the enzyme at 70°C for 10 min. Then, PCR was performed by SYBR Green (Bio-Rad, USA) on an ABI PRISM 7900HT detection system (Applied Biosystems, USA). All primer sequences included in the present study were purchased from Invitrogen Corporation or Generay Biotech (Shanghai, China) and listed in Supplementary Table 3. The quantification analysis was performed according to the  $2^{-\Delta\Delta C_t}$  methods [93]. Target RNA levels were normalized to GAPDH.

### **Mitochondrial DNA (mtDNA) determination**

Total DNA was extracted from myocardium using phenol/chloroform/isoamyl alcohol (25:24:1), which was followed by isopropanol precipitation. The mtDNA levels were determined through calculating mitochondrial gene cytochrome oxidase subunit 1 (Cox1) (forward 5'-ACT ATA CTA CTA CTA ACA GAC CG-3', reverse 5'-GGT TCT TTT TTT CCG GAG TA-3') against nuclear gene cyclophilin A (forward 5'-ACA CGC CAT AAT GGC ACT GG-3', reverse 5'-CAG TCT TGG CAG TGC AGA T-3') by RT-qPCR via the comparative  $2^{-\Delta\Delta C_t}$  method.

### **Histological analysis**

The heart and lung samples extracted from mice were fixed with 4% paraformaldehyde, implanted in paraffin, and sectioned transversely. Sections at 3  $\mu$ m thickness were subjected to hematoxylin followed by eosin (H&E) staining, Masson's trichrome staining and Sirius Red staining for the tissues injury and collagen accumulation calculation [94] derived from 3 pathologists under a light microscopy (Olympus, Tokyo, Japan).

### **IHC analysis**

For immunostaining of 8-OHdG (ab48508, Abcam), p-NF- $\kappa$ B (ab28856, Abcam) and RIPK3 (ab56164, Abcam), cardiac tissues were incubated in 3% H<sub>2</sub>O<sub>2</sub> for



10 min to block endogenous peroxidase activity. Then, 5% bovine serum albumin (BSA, Shanghai Boao Biotechnology Co., Ltd., Shanghai, China) was used to block non-specific binding for 1 h. Then, heart tissues were incubated with primary antibodies (dilutions at 1:200) overnight at 4°C, followed by incubation with secondary antibodies at 37°C for 30 min. After washing with PBS, the sections were developed using 3,3'-diaminobenzidine (DAB, Sigma Aldrich) with 0.03% hydrogen peroxide for 5 min. Then, tissue sections were counterstained with hematoxylin for 1 min and observed under a light microscope (Olympus).

### **Mitochondrial function and respiration measurement**

Mitochondrial function was performed through calculating ATP production and mitochondrial potential [95]. The JC-1 Kit (Beyotime, Nanjing, China) was used to measure the change in the mitochondrial membrane potential [96]. The cellular ATP levels were measured using a firefly luciferase-based ATP assay kit (Beyotime) based on a fluorescence technique according to the manufacturer's instructions. As for ATP calculation in heart tissues, ATP Assay Kit (ab83355, Abcam) used the phosphorylation of glycerol to generate a product quantified by colorimetric method. 10 mg of heart tissue was homogenized in 100 µl of ATP assay buffer and centrifuged. The supernatant was then transferred for deproteinization using ice-cold 4 M perchloric acid and 2 M KOH. The analysis was performed according to the manufacturer's instruction. The mPTP opening was measured through calcein-AM/cobalt. The relative mPTP opening rate was measured as the ratio to control group [97]. As for mitochondrial respiration measurement, hearts were cut into longitudinal strips along fiber orientation with a diameter of 1.5 mm. Then, the fiber bundles were transferred to a tube with 2 ml ice-cold relaxation and preservation solution with 50 µg/ml saponin (Sigma-Aldrich) for 20 min permeabilization [98]. Fibers were rinsed with fresh mitochondrial respirometry solution MiR05 (0.5 mM EGTA, 3 mM MgCl<sub>2</sub>, 60 mM K-lactobionate, 10 mM KH<sub>2</sub>PO<sub>4</sub>, 20 mM HEPES, 110 mM sucrose, pH 7.1). 2 mg cardiac fiber was placed in the oxygraph chambers supplemented with MiR05 followed by addition of 10 mM glutamate and 5 mM malate for evaluating complex I-supported Leak respiration rate. Then, 2 mM ADP was added to determine the maximal phosphorylating respiration rate.

### **Cellular viability and intracellular ROS**

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was performed to analyze the cell viability according to the manufacturer's

instructions (Beyotime). Absorbance was determined at 570 nm. The relative cell viability was recorded as a ratio to that in the control group. After various treatments, 1.5 mL of dichloro-dihydro-fluorescein diacetate (DCFH-DA) (10.0 µM, Sigma-Aldrich) was added at 37°C for 25 min, and then the samples were analyzed using a fluorescence microscopy (Olympus, Tokyo, Japan).

### **Statistical analysis**

All data in this study are expressed as the mean ± standard error of the mean (SEM). For comparison between two groups, Student's two-tailed t-test was used. For comparisons among multiple groups, parametric statistical analysis was conducted using one-way analysis of variance (ANOVA) with Tukey post hoc test. A P value < 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad PRISM (version 6.0 for mac; Graph Pad Software).

### **CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

### **FUNDING**

This study was jointly supported by (1) the National Natural Science Foundation of China (NSFC Grant No.: 81703527); (2) the Chongqing Research Program of Basic Research and Frontier Technology (Grant Nos.: cstc2017jcyjAX0356, cstc2018jcyjA3686, cstc2018jcyjAX0784, cstc2018jcyjA1472, cstc2018jcyjAX0811, cstc2018jcyjA3533, and KJZD-M201801601); (3) the School-Level Research Program of Chongqing University of Education (Grant Nos.: KY201710B and 17GZKP01); (4) Advanced Programs of Post-Doctor of Chongqing (Grant No.: 2017LY39); (5) the Science and Technology Research Program of Chongqing Education Commission of China (Grant Nos.: KJQN201901608, KJQN201901615, and KJ1601402); (6) the Children's Research Institute of the National Center for Schooling Development Program and Chongqing University of Education (Grant No.: CSDP19FSO1108); and (7) the Chongqing Professional Talents Plan for Innovation and Entrepreneurship Demonstration Team (Grant No.: CQCZY201903258).

### **REFERENCES**

1. Luo L, Jiang J, Zhang G, Wang L, Wang Z, Yang J, Yu C. Stroke mortality attributable to ambient particulate matter pollution from 1990 to 2015 in China: an age-period-cohort and spatial autocorrelation analysis. *Int J Environ Res Public Health*. 2017; 14:772.

- <https://doi.org/10.3390/ijerph14070772>  
PMID:28703768
2. Ye X, Peng L, Kan H, Wang W, Geng F, Mu Z, Zhou J, Yang D. Acute effects of particulate air pollution on the incidence of coronary heart disease in Shanghai, China. *PLoS One*. 2016; 11:e0151119.  
<https://doi.org/10.1371/journal.pone.0151119>  
PMID:26942767
3. Jin Y, Wu W, Zhang W, Zhao Y, Wu Y, Ge G, Ba Y, Guo Q, Gao T, Chi X, Hao H, Wang J, Feng F. Involvement of EGF receptor signaling and NLRP12 inflammasome in fine particulate matter-induced lung inflammation in mice. *Environ Toxicol*. 2017; 32:1121–34.  
<https://doi.org/10.1002/tox.22308>  
PMID:27377055
4. Sint T, Donohue JF, Ghio AJ. Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease. *Inhal Toxicol*. 2008; 20:25–29.  
<https://doi.org/10.1080/08958370701758759>  
PMID:18236218
5. Sancini G, Farina F, Battaglia C, Cifola I, Mangano E, Mantecca P, Camatini M, Palestini P. Health risk assessment for air pollutants: alterations in lung and cardiac gene expression in mice exposed to Milano winter fine particulate matter (PM2.5). *PLoS One*. 2014; 9:e109685.  
<https://doi.org/10.1371/journal.pone.0109685>  
PMID:25296036
6. Haberzettl P, O'Toole TE, Bhatnagar A, Conklin DJ. Exposure to fine particulate air pollution causes vascular insulin resistance by inducing pulmonary oxidative stress. *Environ Health Perspect*. 2016; 124:1830–39.  
<https://doi.org/10.1289/EHP212> PMID:27128347
7. Zheng Z, Zhang X, Wang J, Dandekar A, Kim H, Qiu Y, Xu X, Cui Y, Wang A, Chen LC, Rajagopalan S, Sun Q, Zhang K. Exposure to fine airborne particulate matters induces hepatic fibrosis in murine models. *J Hepatol*. 2015; 63:1397–404.  
<https://doi.org/10.1016/j.jhep.2015.07.020>  
PMID:26220751
8. Mendez R, Zheng Z, Fan Z, Rajagopalan S, Sun Q, Zhang K. Exposure to fine airborne particulate matter induces macrophage infiltration, unfolded protein response, and lipid deposition in white adipose tissue. *Am J Transl Res*. 2013; 5:224–34.  
PMID:23573366
9. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. *Diabetes*. 2011; 60:3055–66.  
<https://doi.org/10.2337/db11-0807>  
PMID:22025779
10. Zhang Y, Sano M, Shinmura K, Tamaki K, Katsumata Y, Matsushashi T, Morizane S, Ito H, Hishiki T, Endo J, Zhou H, Yuasa S, Kaneda R, et al. 4-hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway. *J Mol Cell Cardiol*. 2010; 49:576–86.  
<https://doi.org/10.1016/j.yjmcc.2010.05.011>  
PMID:20685357
11. Bai Y, Cui W, Xin Y, Miao X, Barati MT, Zhang C, Chen Q, Tan Y, Cui T, Zheng Y, Cai L. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. *J Mol Cell Cardiol*. 2013; 57:82–95.  
<https://doi.org/10.1016/j.yjmcc.2013.01.008>  
PMID:23353773
12. Zhang J, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher JM, Shibahara S, Itoh K, Yamamoto M. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. *Mol Cell Biol*. 2006; 26:7942–52.  
<https://doi.org/10.1128/MCB.00700-06>  
PMID:16923960
13. Cho HY, Reddy SP, Yamamoto M, Kleeberger SR. The transcription factor NRF2 protects against pulmonary fibrosis. *FASEB J*. 2004; 18:1258–60.  
<https://doi.org/10.1096/fj.03-1127fje> PMID:15208274
14. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. *Pharmacol Res*. 2008; 58:262–70.  
<https://doi.org/10.1016/j.phrs.2008.09.003>  
PMID:18838122
15. Xu MX, Zhu YF, Chang HF, Liang Y. Nanoceria restrains PM2.5-induced metabolic disorder and hypothalamus inflammation by inhibition of astrocytes activation related NF-κB pathway in Nrf2 deficient mice. *Free Radic Biol Med*. 2016; 99:259–72.  
<https://doi.org/10.1016/j.freeradbiomed.2016.08.021>  
PMID:27554971
16. Chenxu G, Minxuan X, Yuting Q, Tingting G, Jinxiao L, Mingxing W, Sujun W, Yongjie M, Deshuai L, Qiang L, Linfeng H, Jun T. iRhom2 loss alleviates renal injury in long-term PM2.5-exposed mice by suppression of inflammation and oxidative stress. *Redox Biol*. 2018; 19:147–57.  
<https://doi.org/10.1016/j.redox.2018.08.009>  
PMID:30165303
17. Xu MX, Ge CX, Qin YT, Gu TT, Lou DS, Li Q, Hu LF, Feng J, Huang P, Tan J. Prolonged PM2.5 exposure elevates risk of oxidative stress-driven nonalcoholic fatty liver

- disease by triggering increase of dyslipidemia. *Free Radic Biol Med.* 2019; 130:542–56.  
<https://doi.org/10.1016/j.freeradbiomed.2018.11.016>  
PMID:30465824
18. Zhang H, Xue L, Li B, Tian H, Zhang Z, Tao S. Therapeutic potential of bixin in PM2.5 particles-induced lung injury in an Nrf2-dependent manner. *Free Radic Biol Med.* 2018; 126:166–76.  
<https://doi.org/10.1016/j.freeradbiomed.2018.08.015>  
PMID:30120979
19. Li N, Sioutas C, Cho A, Schmitz D, Misra C, Sempf J, Wang M, Oberley T, Froines J, Nel A. Ultrafine particulate pollutants induce oxidative stress and mitochondrial damage. *Environ Health Perspect.* 2003; 111:455–60.  
<https://doi.org/10.1289/ehp.6000> PMID:12676598
20. Meyer JN, Leung MC, Rooney JP, Sandoel A, Hengartner MO, Kisby GE, Bess AS. Mitochondria as a target of environmental toxicants. *Toxicol Sci.* 2013; 134:1–17.  
<https://doi.org/10.1093/toxsci/kft102> PMID:23629515
21. Hall AR, Burke N, Dongworth RK, Hausenloy DJ. Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease. *Br J Pharmacol.* 2014; 171:1890–906.  
<https://doi.org/10.1111/bph.12516>  
PMID:24328763
22. Xia T, Kovochich M, Nel AE. Impairment of mitochondrial function by particulate matter (PM) and their toxic components: implications for PM-induced cardiovascular and lung disease. *Front Biosci.* 2007; 12:1238–46.  
<https://doi.org/10.2741/2142> PMID:17127377
23. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D, Komuves L, Ferrando RE, French DM, Webster J, Roose-Girma M, Warming S, Dixit VM. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. *Science.* 2014; 343:1357–60.  
<https://doi.org/10.1126/science.1249361>  
PMID:24557836
24. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, Vince JE, Lawlor KE, Ninnis RL, Anderton H, Hall C, Spall SK, Phesse TJ, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. *Cell.* 2014; 157:1175–88.  
<https://doi.org/10.1016/j.cell.2014.04.019>  
PMID:24813849
25. Zhou H, Zhu P, Guo J, Hu N, Wang S, Li D, Hu S, Ren J, Cao F, Chen Y. Ripk3 induces mitochondrial apoptosis via inhibition of FUNDC1 mitophagy in cardiac IR injury. *Redox Biol.* 2017; 13:498–507.  
<https://doi.org/10.1016/j.redox.2017.07.007>  
PMID:28732308
26. Chenxu G, Minxuan X, Yuting Q, Tingting G, Jing F, Jinxiao L, Sujun W, Yongjie M, Deshuai L, Qiang L, Linfeng H, Xuyuan N, Mingxing W, et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress. *Free Radic Biol Med.* 2019; 134:23–41.  
<https://doi.org/10.1016/j.freeradbiomed.2018.12.034>  
PMID:30599260
27. Sureshbabu A, Patino E, Ma KC, Laursen K, Finkelsztajn EJ, Akchurin O, Muthukumar T, Ryter SW, Gudas L, Choi AM, Choi ME. RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial dysfunction. *JCI Insight.* 2018; 3:98411.  
<https://doi.org/10.1172/jci.insight.98411>  
PMID:29875323
28. Li X, Lan Y, Wang Y, Nie M, Lu Y, Zhao E. Telmisartan suppresses cardiac hypertrophy by inhibiting cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathway. *Mol Med Rep.* 2017; 15:2574–82.  
<https://doi.org/10.3892/mmr.2017.6318>  
PMID:28447738
29. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthivel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, Molkentin JD. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. *J Clin Invest.* 2010; 120:3680–87.  
<https://doi.org/10.1172/JCI43171>  
PMID:20890047
30. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I, Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. *Nature.* 2012; 485:251–55.  
<https://doi.org/10.1038/nature10992>  
PMID:22535248
31. Schiattarella GG, Hill JA. Therapeutic targeting of autophagy in cardiovascular disease. *J Mol Cell Cardiol.* 2016; 95:86–93.  
<https://doi.org/10.1016/j.yjmcc.2015.11.019>  
PMID:26602750
32. Dai P, Shen D, Shen J, Tang Q, Xi M, Li Y, Li C. The roles of Nrf2 and autophagy in modulating inflammation mediated by TLR4 - NFκB in A549 cell exposed to layer house particulate matter 2.5 (PM<sub>2.5</sub>). *Chemosphere.* 2019; 235:1134–45.  
<https://doi.org/10.1016/j.chemosphere.2019.07.002>  
PMID:31561304



33. O Farrell F, Rusten TE, Stenmark H. Phosphoinositide 3-kinases as accelerators and brakes of autophagy. *FEBS J.* 2013; 280:6322–37. <https://doi.org/10.1111/febs.12486> PMID:[23953235](https://pubmed.ncbi.nlm.nih.gov/23953235/)
34. Wirawan E, Lippens S, Vanden Berghe T, Romagnoli A, Fimia GM, Piacentini M, Vandenabeele P. Beclin1: a role in membrane dynamics and beyond. *Autophagy.* 2012; 8:6–17. <https://doi.org/10.4161/auto.8.1.16645> PMID:[22170155](https://pubmed.ncbi.nlm.nih.gov/22170155/)
35. Meyer G, Czompa A, Reboul C, Csepanyi E, Czegledi A, Bak I, Balla G, Balla J, Tosaki A, Lekli I. The cellular autophagy markers Beclin-1 and LC3B-II are increased during reperfusion in fibrillated mouse hearts. *Curr Pharm Des.* 2013; 19:6912–18. <https://doi.org/10.2174/138161281939131127122510> PMID:[23590156](https://pubmed.ncbi.nlm.nih.gov/23590156/)
36. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science.* 2003; 300:1140–42. <https://doi.org/10.1126/science.1082889> PMID:[12750520](https://pubmed.ncbi.nlm.nih.gov/12750520/)
37. Regenold WT, Phatak P, Makley MJ, Stone RD, Kling MA. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. *J Neurol Sci.* 2008; 275:106–12. <https://doi.org/10.1016/j.jns.2008.07.032> PMID:[18783801](https://pubmed.ncbi.nlm.nih.gov/18783801/)
38. Zhang H, Li Y, Hou X, Zhang L, Wang T. Medium-chain TAG improve energy metabolism and mitochondrial biogenesis in the liver of intra-uterine growth-retarded and normal-birth-weight weanling piglets. *Br J Nutr.* 2016; 115:1521–30. <https://doi.org/10.1017/S0007114516000404> PMID:[26960981](https://pubmed.ncbi.nlm.nih.gov/26960981/)
39. Liang M, Jin S, Wu DD, Wang MJ, Zhu YC. Hydrogen sulfide improves glucose metabolism and prevents hypertrophy in cardiomyocytes. *Nitric Oxide.* 2015; 46:114–22. <https://doi.org/10.1016/j.niox.2014.12.007> PMID:[25524832](https://pubmed.ncbi.nlm.nih.gov/25524832/)
40. Wang S, Xu Z, Yin H, Min Y, Li S. Alleviation mechanisms of selenium on cadmium-spiked in chicken ovarian tissue: perspectives from autophagy and energy metabolism. *Biol Trace Elem Res.* 2018; 186:521–28. <https://doi.org/10.1007/s12011-018-1341-y> PMID:[29679350](https://pubmed.ncbi.nlm.nih.gov/29679350/)
41. Maio N, Kim KS, Singh A, Rouault TA. A Single Adaptable Co-chaperone-Scaffold Complex Delivers Nascent Iron-Sulfur Clusters to Mammalian Respiratory Chain Complexes I-III. *Cell Metab.* 2017; 25:945–953.e6. <https://doi.org/10.1016/j.cmet.2017.03.010> PMID:[28380382](https://pubmed.ncbi.nlm.nih.gov/28380382/)
42. Holmström MH, Tom RZ, Björnholm M, Garcia-Roves PM, Zierath JR. Effect of leptin treatment on mitochondrial function in obese leptin-deficient ob/ob mice. *Metabolism.* 2013; 62:1258–67. <https://doi.org/10.1016/j.metabol.2013.04.001> PMID:[23664724](https://pubmed.ncbi.nlm.nih.gov/23664724/)
43. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN, Burgess SC, Mangelsdorf DJ, Kliewer SA. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1 $\alpha$  pathway. *Cell Metab.* 2011; 13:729–38. <https://doi.org/10.1016/j.cmet.2011.03.019> PMID:[21641554](https://pubmed.ncbi.nlm.nih.gov/21641554/)
44. Zhao K, Wen LB. DMF attenuates cisplatin-induced kidney injury via activating Nrf2 signaling pathway and inhibiting NF- $\kappa$ B signaling pathway. *Eur Rev Med Pharmacol Sci.* 2018; 22:8924–31. <https://doi.org/10.26355/eurev.201812.16662> PMID:[30575936](https://pubmed.ncbi.nlm.nih.gov/30575936/)
45. Draheim T, Liessem A, Scheld M, Wilms F, Weißflog M, Denecke B, Kensler TW, Zendedel A, Beyer C, Kipp M, Wruck CJ, Fragoulis A, Clarner T. Activation of the astrocytic Nrf2/ARE system ameliorates the formation of demyelinating lesions in a multiple sclerosis animal model. *Glia.* 2016; 64:2219–30. <https://doi.org/10.1002/glia.23058> PMID:[27641725](https://pubmed.ncbi.nlm.nih.gov/27641725/)
46. Li N, Alam J, Venkatesan MI, Eiguren-Fernandez A, Schmitz D, Di Stefano E, Slaughter N, Killeen E, Wang X, Huang A, Wang M, Miguel AH, Cho A, et al. Nrf2 is a key transcription factor that regulates antioxidant defense in macrophages and epithelial cells: protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals. *J Immunol.* 2004; 173:3467–81. <https://doi.org/10.4049/jimmunol.173.5.3467> PMID:[15322212](https://pubmed.ncbi.nlm.nih.gov/15322212/)
47. Ulrich MM, Alink GM, Kumarathasan P, Vincent R, Boere AJ, Cassee FR. Health effects and time course of particulate matter on the cardiopulmonary system in rats with lung inflammation. *J Toxicol Environ Health A.* 2002; 65:1571–95. <https://doi.org/10.1080/00984100290071676> PMID:[12396869](https://pubmed.ncbi.nlm.nih.gov/12396869/)
48. Li R, Kou X, Geng H, Xie J, Yang Z, Zhang Y, Cai Z, Dong C. Effect of ambient PM(2.5) on lung mitochondrial damage and fusion/fission gene expression in rats. *Chem Res Toxicol.* 2015; 28:408–18. <https://doi.org/10.1021/tx500372j> PMID:[25560372](https://pubmed.ncbi.nlm.nih.gov/25560372/)

49. Papaiahgari S, Zhang Q, Kleeberger SR, Cho HY, Reddy SP. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. *Antioxid Redox Signal*. 2006; 8:43–52.  
<https://doi.org/10.1089/ars.2006.8.43> PMID:16487036
50. Cozzi E, Hazarika S, Stallings HW 3rd, Cascio WE, Devlin RB, Lust RM, Wingard CJ, Van Scott MR. Ultrafine particulate matter exposure augments ischemia-reperfusion injury in mice. *Am J Physiol Heart Circ Physiol*. 2006; 291:H894–903.  
<https://doi.org/10.1152/ajpheart.01362.2005> PMID:16582015
51. Pardo M, Xu F, Shemesh M, Qiu X, Barak Y, Zhu T, Rudich Y. Nrf2 protects against diverse PM<sub>2.5</sub> components-induced mitochondrial oxidative damage in lung cells. *Sci Total Environ*. 2019; 669:303–13.  
<https://doi.org/10.1016/j.scitotenv.2019.01.436> PMID:30878937
52. Wei Y, Cao XN, Tang XL, Shen LJ, Lin T, He DW, Wu SD, Wei GH. Urban fine particulate matter (PM<sub>2.5</sub>) exposure destroys blood-testis barrier (BTB) integrity through excessive ROS-mediated autophagy. *Toxicol Mech Methods*. 2018; 28:302–19.  
<https://doi.org/10.1080/15376516.2017.1410743> PMID:29179619
53. Deng X, Zhang F, Rui W, Long F, Wang L, Feng Z, Chen D, Ding W. PM<sub>2.5</sub>-induced oxidative stress triggers autophagy in human lung epithelial A549 cells. *Toxicol In Vitro*. 2013; 27:1762–70.  
<https://doi.org/10.1016/j.tiv.2013.05.004> PMID:23685237
54. Jang J, Wang Y, Lalli MA, Guzman E, Godshalk SE, Zhou H, Kosik KS. Primary cilium-autophagy-Nrf2 (PAN) axis activation commits human embryonic stem cells to a neuroectoderm fate. *Cell*. 2016; 165:410–20.  
<https://doi.org/10.1016/j.cell.2016.02.014> PMID:27020754
55. Qin Q, Qu C, Niu T, Zang H, Qi L, Lyu L, Wang X, Nagarkatti M, Nagarkatti P, Janicki JS, Wang XL, Cui T. Nrf2-mediated cardiac maladaptive remodeling and dysfunction in a setting of autophagy insufficiency. *Hypertension*. 2016; 67:107–17.  
<https://doi.org/10.1161/HYPERTENSIONAHA.115.06062> PMID:26573705
56. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, Su IJ, Chang CR, Tsai YS. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. *Mol Cell Biol*. 2012; 32:309–19.  
<https://doi.org/10.1128/MCB.05603-11> PMID:22083962
57. Xu J, Zhang W, Lu Z, Zhang F, Ding W. Airborne PM<sub>2.5</sub>-induced hepatic insulin resistance by Nrf2/JNK-mediated signaling pathway. *Int J Environ Res Public Health*. 2017; 14:787.  
<https://doi.org/10.3390/ijerph14070787> PMID:28708100
58. Foresti R, Bucolo C, Platania CM, Drago F, Dubois-Randé JL, Motterlini R. Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. *Pharmacol Res*. 2015; 99:296–307.  
<https://doi.org/10.1016/j.phrs.2015.07.006> PMID:26188148
59. Meher AK, Sharma PR, Lira VA, Yamamoto M, Kensler TW, Yan Z, Leitinger N. Nrf2 deficiency in myeloid cells is not sufficient to protect mice from high-fat diet-induced adipose tissue inflammation and insulin resistance. *Free Radic Biol Med*. 2012; 52:1708–15.  
<https://doi.org/10.1016/j.freeradbiomed.2012.02.022> PMID:22370093
60. Grahame TJ, Schlesinger RB. Oxidative stress-induced telomeric erosion as a mechanism underlying airborne particulate matter-related cardiovascular disease. *Part Fibre Toxicol*. 2012; 9:21.  
<https://doi.org/10.1186/1743-8977-9-21> PMID:22713210
61. Lee MS, Eum KD, Fang SC, Rodrigues EG, Modest GA, Christiani DC. Oxidative stress and systemic inflammation as modifiers of cardiac autonomic responses to particulate air pollution. *Int J Cardiol*. 2014; 176:166–70.  
<https://doi.org/10.1016/j.ijcard.2014.07.012> PMID:25074558
62. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, Kong AN. Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis. *Biochem Pharmacol*. 2008; 76:1485–89.  
<https://doi.org/10.1016/j.bcp.2008.07.017> PMID:18694732
63. Bayram B, Ozcelik B, Grimm S, Roeder T, Schrader C, Ernst IM, Wagner AE, Grune T, Frank J, Rimbach G. A diet rich in olive oil phenolics reduces oxidative stress in the heart of SAMP8 mice by induction of Nrf2-dependent gene expression. *Rejuvenation Res*. 2012; 15:71–81.  
<https://doi.org/10.1089/rej.2011.1245> PMID:22236145
64. Fu RQ, Hu DP, Hu YB, Hong L, Sun QF, Ding JG. miR-21 promotes α-SMA and collagen I expression in hepatic stellate cells via the Smad7 signaling pathway. *Mol Med Rep*. 2017; 16:4327–33.

- <https://doi.org/10.3892/mmr.2017.7054>  
PMID:[28731181](https://pubmed.ncbi.nlm.nih.gov/28731181/)
65. Szóstek-Mioduchowska AZ, Lukasiak K, Skarzynski DJ, Okuda K. Effect of transforming growth factor  $\beta$ 1 on  $\alpha$ -smooth muscle actin and collagen expression in equine endometrial fibroblasts. *Theriogenology*. 2019; 124:9–17.  
<https://doi.org/10.1016/j.theriogenology.2018.10.005>  
PMID:[30321755](https://pubmed.ncbi.nlm.nih.gov/30321755/)
66. Qiu YN, Wang GH, Zhou F, Hao JJ, Tian L, Guan LF, Geng XK, Ding YC, Wu HW, Zhang KZ. PM2.5 induces liver fibrosis via triggering ROS-mediated mitophagy. *Ecotoxicol Environ Saf*. 2019; 167:178–187.  
<https://doi.org/10.1016/j.ecoenv.2018.08.050>  
PMID:[30336408](https://pubmed.ncbi.nlm.nih.gov/30336408/)
67. Xu Z, Li Z, Liao Z, Gao S, Hua L, Ye X, Wang Y, Jiang S, Wang N, Zhou D, Deng X. PM<sub>2.5</sub> induced pulmonary fibrosis in vivo and in vitro. *Ecotoxicol Environ Saf*. 2019; 171:112–21.  
<https://doi.org/10.1016/j.ecoenv.2018.12.061>  
PMID:[30597315](https://pubmed.ncbi.nlm.nih.gov/30597315/)
68. Gu LZ, Sun H, Chen JH. Histone deacetylases 3 deletion restrains PM2.5-induced mice lung injury by regulating NF- $\kappa$ B and TGF- $\beta$ /Smad2/3 signaling pathways. *Biomed Pharmacother*. 2017; 85:756–62.  
<https://doi.org/10.1016/j.biopha.2016.11.094>  
PMID:[27919737](https://pubmed.ncbi.nlm.nih.gov/27919737/)
69. Xia WR, Fu W, Wang Q, Zhu X, Xing WW, Wang M, Xu DQ, Xu DG. Autophagy Induced FHL2 Upregulation Promotes IL-6 Production by Activating the NF- $\kappa$ B Pathway in Mouse Aortic Endothelial Cells after Exposure to PM2.5. *Int J Mol Sci*. 2017; 18:1484.  
<https://doi.org/10.3390/ijms18071484>  
PMID:[28714941](https://pubmed.ncbi.nlm.nih.gov/28714941/)
70. Ma MW, Wang J, Dhandapani KM, Brann DW. Deletion of NADPH oxidase 4 reduces severity of traumatic brain injury. *Free Radic Biol Med*. 2018; 117:66–75.  
<https://doi.org/10.1016/j.freeradbiomed.2018.01.031>  
PMID:[29391196](https://pubmed.ncbi.nlm.nih.gov/29391196/)
71. Liu H, Zhao L, Yue L, Wang B, Li X, Guo H, Ma Y, Yao C, Gao L, Deng J, Li L, Feng D, Qu Y. Pterostilbene attenuates early brain injury following subarachnoid hemorrhage via inhibition of the NLRP3 inflammasome and Nox2-related oxidative stress. *Mol Neurobiol*. 2017; 54:5928–40.  
<https://doi.org/10.1007/s12035-016-0108-8>  
PMID:[27665283](https://pubmed.ncbi.nlm.nih.gov/27665283/)
72. Tigchelaar W, de Jong AM, Bloks VW, van Gilst WH, de Boer RA, Silljé HH. Hypertrophy induced KIF5B controls mitochondrial localization and function in neonatal rat cardiomyocytes. *J Mol Cell Cardiol*. 2016; 97:70–81.  
<https://doi.org/10.1016/j.yjmcc.2016.04.005>  
PMID:[27094714](https://pubmed.ncbi.nlm.nih.gov/27094714/)
73. Zhou H, Zhang Y, Hu S, Shi C, Zhu P, Ma Q, Jin Q, Cao F, Tian F, Chen Y. Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis. *J Pineal Res*. 2017; 63:e12413.  
<https://doi.org/10.1111/jpi.12413>  
PMID:[28398674](https://pubmed.ncbi.nlm.nih.gov/28398674/)
74. Li R, Kou X, Geng H, Xie J, Tian J, Cai Z, Dong C. Mitochondrial damage: an important mechanism of ambient PM2.5 exposure-induced acute heart injury in rats. *J Hazard Mater*. 2015; 287:392–401.  
<https://doi.org/10.1016/j.jhazmat.2015.02.006>  
PMID:[25677476](https://pubmed.ncbi.nlm.nih.gov/25677476/)
75. Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM, Dorn GW 2nd, Yellon DM, Hausenloy DJ. Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction. *Cell Death Dis*. 2016; 7:e2238.  
<https://doi.org/10.1038/cddis.2016.139>  
PMID:[27228353](https://pubmed.ncbi.nlm.nih.gov/27228353/)
76. Ferreira-da-Silva A, Valacca C, Rios E, Pópulo H, Soares P, Sobrinho-Simões M, Scorrano L, Máximo V, Campello S. Mitochondrial dynamics protein Drp1 is overexpressed in oncocyctic thyroid tumors and regulates cancer cell migration. *PLoS One*. 2015; 10:e0122308.  
<https://doi.org/10.1371/journal.pone.0122308>  
PMID:[25822260](https://pubmed.ncbi.nlm.nih.gov/25822260/)
77. Atkins K, Dasgupta A, Chen KH, Mewburn J, Archer SL. The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: implications for human disease. *Clin Sci (Lond)*. 2016; 130:1861–74.  
<https://doi.org/10.1042/CS20160030> PMID:[27660309](https://pubmed.ncbi.nlm.nih.gov/27660309/)
78. Huang DD, Fan SD, Chen XY, Yan XL, Zhang XZ, Ma BW, Yu DY, Xiao WY, Zhuang CL, Yu Z. Nrf2 deficiency exacerbates frailty and sarcopenia by impairing skeletal muscle mitochondrial biogenesis and dynamics in an age-dependent manner. *Exp Gerontol*. 2019; 119:61–73.  
<https://doi.org/10.1016/j.exger.2019.01.022>  
PMID:[30690066](https://pubmed.ncbi.nlm.nih.gov/30690066/)
79. Holmström KM, Kostov RV, Dinkova-Kostova AT. The multifaceted role of Nrf2 in mitochondrial function. *Curr Opin Toxicol*. 2016; 1:80–91.  
<https://doi.org/10.1016/j.cotox.2016.10.002>  
PMID:[28066829](https://pubmed.ncbi.nlm.nih.gov/28066829/)
80. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. *Biochim Biophys Acta*. 2010; 1797:897–906.




- <https://doi.org/10.1016/j.bbabbio.2010.01.032>  
PMID:20122895
81. Li J, Ichikawa T, Janicki JS, Cui T. Targeting the Nrf2 pathway against cardiovascular disease. *Expert Opin Ther Targets*. 2009; 13:785–94.  
<https://doi.org/10.1517/14728220903025762>  
PMID:19530984
82. Bai Y, Wang X, Zhao S, Ma C, Cui J, Zheng Y. Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation. *Oxid Med Cell Longev*. 2015; 2015:407580.  
<https://doi.org/10.1155/2015/407580> PMID:26583056
83. Zhu J, Wang Q, Li C, Lu Y, Hu H, Qin B, Xun Y, Zhu Y, Wu Y, Zhang J, Wang S. Inhibiting inflammation and modulating oxidative stress in oxalate-induced nephrolithiasis with the Nrf2 activator dimethyl fumarate. *Free Radic Biol Med*. 2019; 134:9–22.  
<https://doi.org/10.1016/j.freeradbiomed.2018.12.033>  
PMID:30599261
84. Ying Z, Xu X, Bai Y, Zhong J, Chen M, Liang Y, Zhao J, Liu D, Morishita M, Sun Q, Spino C, Brook RD, Harkema JR, Rajagopalan S. Long-term exposure to concentrated ambient PM<sub>2.5</sub> increases mouse blood pressure through abnormal activation of the sympathetic nervous system: a role for hypothalamic inflammation. *Environ Health Perspect*. 2014; 122:79–86.  
<https://doi.org/10.1289/ehp.1307151>  
PMID:24240275
85. Ogino K, Zhang R, Takahashi H, Takemoto K, Kubo M, Murakami I, Wang DH, Fujikura Y. Allergic airway inflammation by nasal inoculation of particulate matter (PM<sub>2.5</sub>) in NC/Nga mice. *PLoS One*. 2014; 9:e92710.  
<https://doi.org/10.1371/journal.pone.0092710>  
PMID:24671176
86. Sagona JA, Shalat SL, Wang Z, Ramagopal M, Black K, Hernandez M, Mainelis G. Comparison of particulate matter exposure estimates in young children from personal sampling equipment and a robotic sampler. *J Expo Sci Environ Epidemiol*. 2017; 27:299–305.  
<https://doi.org/10.1038/jes.2016.24> PMID:27168394
87. Yu J, Li K, Xu J. Indoor PM<sub>2.5</sub> from coal combustion aggravates ovalbumin-induced asthma-like airway inflammation in BALB/c mice. *Am J Physiol Lung Cell Mol Physiol*. 2019; 317:L29–38.  
<https://doi.org/10.1152/ajplung.00012.2019>  
PMID:30969813
88. Rossello X, Burke N, Stoppe C, Bernhagen J, Davidson SM, Yellon DM. Exogenous administration of recombinant MIF at physiological concentrations failed to attenuate infarct size in a Langendorff perfused isolated mouse heart model. *Cardiovasc Drugs Ther*. 2016; 30:445–53.  
<https://doi.org/10.1007/s10557-016-6673-2>  
PMID:27335054
89. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M, Omiya S, Mizote I, Matsumura Y, Asahi M, Nishida K, Hori M, Mizushima N, Otsu K. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. *Nat Med*. 2007; 13:619–24.  
<https://doi.org/10.1038/nm1574> PMID:17450150
90. Ryu Y, Jin L, Kee HJ, Piao ZH, Cho JY, Kim GR, Choi SY, Lin MQ, Jeong MH. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. *Sci Rep*. 2016; 6:34790.  
<https://doi.org/10.1038/srep34790>  
PMID:27703224
91. Chen C, Zou LX, Lin QY, Yan X, Bi HL, Xie X, Wang S, Wang QS, Zhang YL, Li HH. Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload. *Redox Biol*. 2019; 20:390–401.  
<https://doi.org/10.1016/j.redox.2018.10.021>  
PMID:30412827
92. Grohm J, Kim SW, Mamrak U, Tobaben S, Cassidy-Stone A, Nunnari J, Plesnila N, Culmsee C. Inhibition of Drp1 provides neuroprotection in vitro and in vivo. *Cell Death Differ*. 2012; 19:1446–58.  
<https://doi.org/10.1038/cdd.2012.18>  
PMID:22388349
93. Zhao L, Qi Y, Xu L, Tao X, Han X, Yin L, Peng J. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. *Redox Biol*. 2018; 15:284–96.  
<https://doi.org/10.1016/j.redox.2017.12.013>  
PMID:29304479
94. Ding S, Yu L, An B, Zhang G, Yu P, Wang Z. Combination effects of airborne particulate matter exposure and high-fat diet on hepatic fibrosis through regulating the ROS-endoplasmic reticulum stress-TGFβ/SMADs axis in mice. *Chemosphere*. 2018; 199:538–45.  
<https://doi.org/10.1016/j.chemosphere.2018.02.082>  
PMID:29455124
95. Kuznetsov AV, Margreiter R, Amberger A, Saks V, Grimm M. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. *Biochim Biophys Acta*. 2011; 1813:1144–52.  
<https://doi.org/10.1016/j.bbamcr.2011.03.002>  
PMID:21406203
96. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the

- amyloid beta peptide in Alzheimer's disease. *Redox Biol.* 2018; 14:450–64.  
<https://doi.org/10.1016/j.redox.2017.10.014>  
PMID:[29080524](https://pubmed.ncbi.nlm.nih.gov/29080524/)
97. Shi C, Cai Y, Li Y, Li Y, Hu N, Ma S, Hu S, Zhu P, Wang W, Zhou H. Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways. *Redox Biol.* 2018; 14:59–71.  
<https://doi.org/10.1016/j.redox.2017.08.013>  
PMID:[28869833](https://pubmed.ncbi.nlm.nih.gov/28869833/)
98. Lauritzen KH, Kleppa L, Aronsen JM, Eide L, Carlsen H, Haugen ØP, Sjaastad I, Klungland A, Rasmussen LJ, Attramadal H, Storm-Mathisen J, Bergersen LH. Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure. *Am J Physiol Heart Circ Physiol.* 2015; 309:H434–49.  
<https://doi.org/10.1152/ajpheart.00253.2014>  
PMID:[26055793](https://pubmed.ncbi.nlm.nih.gov/26055793/)

## SUPPLEMENTARY MATERIALS

### Supplementary Figure



**Supplementary Figure 1.** (A) Western blot analysis of Nrf2 in lung (up panel) and heart (down panel) tissues from the Nrf2<sup>+/+</sup> mice or Nrf2<sup>-/-</sup> mice (n=8/group). (B) Cardiomyocytes were transfected with siRIPK3 or its corresponding negative control siRNA for 24 h. Then, the cells were collected for western blot analysis of RIPK3 (n=6/group).



## Supplementary Tables

Supplementary Table 1. Components of PM<sub>2.5</sub> (ng/m<sup>3</sup>).

Element	Ambient PM <sub>2.5</sub>
Zinc	11.19 ± 3.71
Arsenic	0.96 ± 0.14
Lanthanum	0.02 ± 0.01
Barium	3.02 ± 0.68
Antimony	0.55 ± 0.24
Molybdenum	0.45 ± 0.23
Titanium	0.83 ± 0.25
Calcium	88.46 ± 12.51
Sulfur	1021.28 ± 346.71
Phosphorus	17.21 ± 2.55
Aluminum	23.44 ± 7.13
Magnesium	26.75 ± 3.96
Sodium	55.19 ± 11.47
Lead	2.91 ± 0.74
Copper	2.45 ± 0.74
Potassium	37.23 ± 8.87
Selenium	0.46 ± 0.04
Cerium	0.04 ± 0.01
Cadmium	0.51 ± 0.06
Strontium	0.36 ± 0.11
Rubidium	0.06 ± 0.01
Nitrogen	0.43 ± 0.51
Cobalt	0.12 ± 0.11
Iron	55.63 ± 13.96
Manganese	1.88 ± 0.63
Chromium	8.47 ± 1.15
Vanadium	0.31 ± 0.19

**Supplementary Table 2. Primary and secondary antibodies used for western blot analysis.**

<b>Name</b>	<b>Catalog</b>	<b>Dilutions</b>	<b>Vendor</b>
TGFβ1	ab93650	1:1000	Abcam
Phospho-NF-κB	ab86299	1:1000	Abcam
NF-κB	ab76311	1:1000	Abcam
IκBα	#4814	1:1000	Cell Signaling Technology
Phospho-IκBα	#2859	1:1000	Cell Signaling Technology
RIPK3	ab56164	1:1000	Abcam
HO1	ab13248	1:1000	Abcam
Nrf2	ab31163	1:1000	Abcam
GCLM	ab126704	1:1000	Abcam
α-SMA	ab32575	1:1000	Abcam
NDUFB8	ab110242	1:1000	Abcam
SDHB	ab14714	1:1000	Abcam
UQCRC1	#459140	1:1000	Invitrogen
MTCO1	ab14705	1:1000	Abcam
TIM23	ab230253	1:1000	Abcam
Phospho-Smad-2	#18338	1:1000	Abcam
Smad-2	#5339	1:1000	Abcam
Keap-1	ab150654	1:1000	Abcam
Phospho-Smad-3	#9523	1:1000	Cell Signaling Technology
Smad-3	#9520	1:1000	Cell Signaling Technology
Beclin1	ab210498	1:1000	Abcam
Vps34	ab124905	1:1000	Abcam
LC3B	ab192890	1:1000	Abcam
ATG5	ab108327	1:1000	Abcam
Rabbit IgG	ab6721	1:4000	Abcam
Mouse IgG	ab6728	1:4000	Abcam
GAPDH	ab8245	1:1000	Abcam

**Supplementary Table 3. Primer sequences for RT-qPCR analysis.**

<b>Gene name</b>	<b>Primer sequence (5→3')</b>
	Forward primer ACCTGCTAGACCACCTGGAG
	Reverse primer CCTTGGCTGTTATCTTCGGTACCGG
	Forward primer GAGGTCACCTCCTATCCTCTGG
	Reverse primer GCCATTTCTCCGACTTTTCTC
	Forward primer AGGCTTCAGTGGTTTGGATG
	Reverse primer CACCAACAGCACCATCGTTA
	Forward primer TTCCTTCGTGACTACTGCCG
	Reverse primer TATAGGTGGTTTCGTGGATGCC
	Forward primer CACCCGTGAAGAATGAAG
	Reverse primer CAGGCAGGAGATTTGTTAG
	Forward primer TGGCCAGATCCTGTCCAAAC
	Reverse primer CATAGATGGCGTTGTTGCGG
	Forward primer GAGACCTGGGCAATGTGACT
	Reverse primer GTTTACTGCGCAATCCCAAT
	Forward primer ATTAACGCGCAGATCATGCA
	Reverse primer TGTCCCCCACCATTGAACTT
	Forward primer TGTGGCTGTGATAAGCAGGA
	Reverse primer TCCCACTAACATCACCACCT
	Forward primer GATTTCTGGACCTTTGTGCCTTT
	Reverse primer TGATGGTGACAGGTTTGTGCT
	Forward primer ACCTGGCCTCTCTACCTTGT
	Reverse primer CCCGTAGGGCGATTACAGTC
	Forward primer GCCACCTTTTGACAGTGATGAG
	Reverse primer AGTGATACTGCCTGCCTGAAG
	Forward primer ATGTCTAAACTCTCAGCCGTA
	Reverse primer ATTGAGCCATAACTTGACAGA
	Forward primer GTAGGGTTACATGGATGCCAGAGA
	Reverse primer GGCAAAAGCTCCTCCAGCAG
	Forward primer CGGTTCCCTAAACTTCACGA
	Reverse primer GCACCATTTTCATTTGTCACG
	Forward primer AGGATGACAATGGCATTGGC



Reverse primer CCGATCGTACATCCGCTTAAC  
Forward primer GCAACCAATCCACCAACAGAAT  
Reverse primer CCGGAAAAGGCGTTAAGTCAC  
Forward primer CCATCACTGCGATCTTCGGCCA  
Reverse primer CAGCGAGCTTGTTTCTGTAGCCCT  
Forward primer GGGGCCTACATCCAAGAGAG  
Reverse primer GCAGAACTTTGTCCCAGAGC  
Forward primer GATGACACGCTCTCCAGTGAAG  
Reverse primer CTCGGGGCTAACAGTACAACC  
Forward primer TATGAAGACCGCCAATGT  
Reverse primer CCGCCAATGATCTTTTC  
Forward primer TTCTGTCTCGCTACCGA  
Reverse primer GTCACCACAATCACCAG  
Forward primer TGCCAAGCTAACTCCAAACC  
Reverse primer GATACAGTCCGCTTCGGGTA  
Forward primer ACTGTGGGCATCAATCTCCTC  
Reverse primer CGGGACAGACAGACGTTCCAGC  
Forward primer CTGCATAACGGTCTGGACTTC  
Reverse primer GCCTTCCACGAACTTCCTCAC  
Forward primer GGTGAAGGTCGGTGTGAACG  
Reverse primer CCCGTAGGGCGATTACAGTC

---